$EYES Successful Human Implantation Wireless Visual Cortical Stimulator

SYLMAR, California, October 25, 2016  —

Provides Proof of Concept for the Ongoing Development of the Orion™ I Visual Cortical Prosthesis

Second Sight Medical Products, Inc. (Nasdaq: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced the first successful implantation and activation of a wireless visual cortical stimulator in a human subject, providing the initial human proof of concept for the ongoing development of the Company’s Orion™ I Visual Cortical Prosthesis (Orion I). In the UCLA study supported by Second Sight, a 30 year old patient was implanted with a wireless multichannel neurostimulation system on the visual cortex and was able to perceive and localize individual phosphenes or spots of light with no significant adverse side effects.

Dr. Robert Greenberg, Chairman of the Board of Second Sight, said, “It is rare that technological development offers such stirring possibilities. This first human test confirms that we are on the right track with our Orion I program to treat blind patients who cannot benefit from the Argus^® II Retinal Prosthesis (Argus II). This initial success in a patient is an exciting and important milestone even though it does not yet include a camera. By bypassing the optic nerve and directly stimulating the visual cortex, the Orion I has the potential to restore useful vision to patients completely blinded due to virtually any reason, including glaucoma, cancer, diabetic retinopathy, or trauma.  Today these individuals have no available therapy and the Orion I offers hope, increasing independence and improving their quality of life.”

“While we still have much work ahead, this successful human proof of concept study gives us renewed energy to move our Orion I development efforts forward,” said Will McGuire, President and CEO at Second Sight.  “We believe this technology will ultimately provide a useful form of vision for the nearly six million people worldwide who are blind but not a candidate for an Argus II retinal prosthesis. We also remain focused on further developing our Argus II technology for patients with Retinitis Pigmentosa, making it more widely available, and exploring its potential to improve the vision of nearly two million patients blinded by Age-Related Macular Degeneration worldwide.”

Dr. Nader Pouratian, the UCLA neurosurgeon who performed the surgery, added, “Based on these results, stimulation of the visual cortex has the potential to restore useful vision to the blind, which is important for independence and improving quality of life.”

This implant was performed as part of a proof of concept clinical trial whose purpose is to demonstrate initial safety and feasibility of human visual cortex stimulation. The initial success of this study, coupled with the significant additional pre-clinical work gathered to-date readies Second Sight to submit an application to the FDA in early 2017 to gain approval for conducting an initial clinical trial of the complete Orion I system, including the camera and glasses. Assuming positive initial results in patients and discussions with regulators, an expanded pivotal clinical trial for global market approvals is then planned.

About Second Sight

Second Sight’s mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus® II Retinal Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit http://www.secondsight.com.

About the Argus® II Retinal Prosthesis System

Second Sight’s Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound outer retinal degeneration such as retinitis pigmentosa (RP). The Argus II works by converting images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina’s remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some useful vision. The system is controlled by software and is upgradeable, which may provide improved performance as new algorithms are developed and tested. Therefore current and future Argus II users may benefit from the continuously improving technology. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Austria, Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, United Kingdom and the United States.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “potentially,” “objectives,” and similar expressions or the negative versions thereof and which also may be identified by their context. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s Annual Report on Form 10-K as filed on March 11, 2016 and the Company’s other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating the Company’s forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

$EXPI #DarrenJames #RealEstate Team Joins @eXpRealty in #Louisiana

Top Producing REALTOR(R) in Baton Rouge Joins Agent-Owned Cloud Brokerage(R)

$OPCO Reports #Record #Q3 2016 #FinancialResults

OurPet’s Company (OTCQX: OPCO) (www.ourpets.com), a leading proprietary pet supply company, today reports record third-quarter revenue of $7.26 million, an increase of 21% compared to revenues of $5.99 million reported in the same period of 2015. Net income for the third quarter ended September 30, 2016, increased 21% to $495,669, or $0.025 per share, compared to $410,450, or $0.020 per share, for the same period of 2015. Third quarter 2015 results included a one-time U.S. Custom exam refund of $94,000. Discounting the $94,000 refund, the adjusted net income between third quarters 2015 and 2016 grew 57%.

“With the resumption of shipments to our major specialty pet retail customer, we were firing on all cylinders this past quarter. The double-digit growth in sales was also driven by a 19% growth in the Food Drug & Mass market segment, as well as initial shipments of our new electronic cat toy, Intelligent Pet Care, and Switchgrass BC cat litter products. With the strong third-quarter sales, we are up almost 10% for the nine months of 2016, more than double the pet industry average,” states Dr. Steven Tsengas, president and CEO of OurPet’s.

Based on initial October sales bookings and the strong acceptance of product innovations, OurPet’s is guardedly optimistic of a strong fourth quarter and fiscal year 2016, with growth thereafter supported by new products and key partnerships.

“Beyond 2016, our strategy is to achieve double-digit growth in sales and net income with an emphasis on developing and launching proprietary, innovative products and entering appropriate new market segments,” says Dr. Tsengas. “We recently announced our new partnership with Paulee Cleantec, Inc. whereby we plan to commercialize its patented technology to develop portable and fixed-base product solutions to safely and conveniently eliminate pet waste.

“In addition, we recently completed contracts with a leading direct TV (DRTV) marketing company to test market several of our new electronic interactive cat toys for a possible DRTV campaign to launch sometime in the second quarter of 2017. The contracts will allow both parties to move forward with what we believe will be the first of several DRTV programs to raise customer awareness for our entire electronic interactive pet toy category. We have many ‘irons in the fire’ and are very excited about the future.”

2016 Third-Quarter Results

Net revenue increased 21% to $7,259,904 versus revenues of $5,986,645 for the same period last year. The approximate $1.3 million increase was due to strong sales in the Pet Specialty and Food, Drug and Mass channels.

Net income increased 20.76% to $495,669 compared to $410,450 for the third quarter of 2015. Net income per diluted share increased to $0.025 compared to $0.021 a year ago and would have been higher if not for an additional 265,573 shares added to the weighted average of common and basic shares used in calculating diluted earnings per share.

As previously mentioned, third quarter 2015 results included a one-time U.S. Custom exam refund of $94,000. Discounting the $94,000 refund, the adjusted net income between third quarters 2015 and 2016 grew 57%.

Gross profit for third quarter 2016 was $2,443,470 compared to $2,012,177 the prior year. Gross profit margin stayed about the same year-over-year at 33.66%.

As of September 30, 2016, OurPet’s reduced total long-term liabilities by $672,008 (-15%), maintained strong liquidity and achieved a Current Ratio of 5.04, and grew stockholder’s equity by $964,773 (+11%).

2016 First Nine Months Results

Net revenue for the first nine months of 2016 increased 10% to $18,872,791 versus revenues of $17,170,795 reported for the same period last year. The year-over-year increase was due to strong Food, Drug, and Mass sales.

Net income for the 2016 period increased 3.4% to $916,882 compared to $886,319 for the same period of 2015. Net income per share increased to $0.045 for the first nine months of 2015 from $0.044 last year.

Gross profit increased 8% to $5,847,171 for the first nine months of 2016 versus the prior year.

About OurPet’s Company

OurPet’s Company designs, produces and markets a broad line of innovative, high-quality accessory and consumable pet products in the U.S. and overseas. Investors and customers may visit www.ourpets.com for more information about our company and its products. OurPet’s websites include www.petzonebrand.com and www.ourpets.com.

Forward-Looking Statements

Certain of the matters set forth in this press release are forward-looking and involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially are the following: business conditions; growth in the industry; general economic conditions; addition or loss of significant customers; the loss of key personnel; product development; competition; risks of doing business abroad; foreign government regulations; fluctuations in foreign currency rates; rising costs for raw materials and sources of supply that may be limited or unavailable from time to time; the timing of orders booked; and the other risks that are described from time to time in OurPet’s SEC reports.

OurPet’s Company
Dr. Steven Tsengas, CEO, 440-343-6500, x111
or
DreamTeamNetwork
512-758-8877 Office
www.DreamTeamNetwork.com
Editor@DreamTeamNetwork.com

$DGLY Many Orders, #BodyCamera, In-Car AV Systems with Integrated #VuLink

Santa Fe, New Mexico Police Department Continues Full-Fleet Deployment of the Total Integrated Solution Including DVM-800 In-Car Video Systems, FirstVu HD Body Cameras and VuLink(TM) Automatic Activation Technology

$WINT Proprietary Aerosolized #KL4 Surfactant Validated in Latest Study

Study Provides Further Validation of Company’s Proprietary Aerosol Delivery Technology Management to Discuss Results on a Conference Call, Tuesday, October 25, 2016 at 8:00 a.m.

WARRINGTON, Pa., Oct. 24, 2016  — Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today released data from a lung deposition study conducted in non-human primates (NHPs) that demonstrates the Company’s proprietary aerosol delivery system (ADS) is capable of delivering aerosolized KL4 surfactant throughout all regions of the lung. The study consisted of a series of experiments in NHPs designed to assess the distribution and deposition of aerosolized KL4 surfactant in the lung when administered using the ADS. The Company is developing the ADS as part of its lead development program, AEROSURF® (lucinactant for inhalation). AEROSURF is currently being studied in a phase 2b clinical trial as a potential noninvasive treatment for respiratory distress syndrome (RDS) in premature infants. The Company will host a conference call and live webcast on Tuesday, October 25, 2016 at 8:00 a.m. EDT to provide additional details of the study results as well as provide an update on the AEROSURF phase 2 program.

“These study results confirm the ability of our aerosol delivery technology to overcome the barriers of successfully aerosolizing and delivering a surfactant with particle sizes appropriate for deep lung delivery with uniform distribution across all regions of the lung,” commented Craig Fraser, President and Chief Executive Officer. “These results not only support the premise of our AEROSURF RDS program, but also complement the clinical evidence seen in our phase 2a trial in premature infants 29 to 34 week gestational age and provide further insight into other potential applications of this novel technology in the future.”

Data from this study were generated from an in vivo distribution study using three NHPs, cynomolgus macaques, which received three-to-ten minute exposures of technetium-labeled KL4 surfactant that was aerosolized using the same model ADS currently being used in the AEROSURF phase 2b clinical program. After administration, researchers immediately acquired 2-D planar images followed by 3-D SPECT images and then a second 2-D planar image to assess overall pulmonary distribution. Additionally, the 3-D SPECT lung data were analyzed using a quantitative methodology whereby regional distribution was assessed across ten equally sized shells (or layers) of the lung, from the innermost shell through the outermost shell.

Results from the analysis of the 2-D planar and 3-D SPECT images show that aerosolized KL4 surfactant, delivered using the ADS via constant flow nasal continuous positive airway pressure (nCPAP), was generally uniformly deposited in all regions of the NHPs lungs (Image 1 – right).

Results from a quantitative analysis further demonstrated that there was generally uniform distribution in all regions of the lung, with an average total lung distribution of 52 percent in the five inner shells and 48 percent in the five outer shells (Chart 1 – right).

“We are extremely pleased with the results of this study because, along with other work we have done, it serves as yet another validation of the potentially transformational capabilities of our ADS device, which aerosolizes our KL4 surfactant in a consistent and controlled flow and delivers it throughout the lungs to the areas where a surfactant needs to reach to produce its beneficial effects,” commented Steve Simonson, M.D, Senior Vice President and Chief Development Officer.

Conference Call and Webcast Details
The Company will host a conference call and webcast (including a slide presentation) at 8:00 a.m. EDT on Tuesday, October 25, 2016 to provide updates on the AEROSURF® phase 2 clinical program and the lung deposition study in non-human primates.

To participate in the live call and take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international). The live webcast, including a slide presentation, can be accessed at http://windtreetx.investorroom.com/events.

A replay of the conference call will be accessible one hour after completion through November 1, 2016 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference number 10095419. An archive of the webcast can be accessed on the Company’s website at http://windtreetx.investorroom.com/events.

About AEROSURF®
Windtree’s lead product candidate is AEROSURF (lucinactant for inhalation), a novel, investigational combination drug/device product that combines the Company’s proprietary KL4 surfactant and aerosolization technologies.  AEROSURF is being developed to potentially reduce or eliminate the need for endotracheal intubation and mechanical ventilation in the treatment of premature infants with respiratory distress syndrome (RDS).  Enrollment is ongoing in a phase 2b clinical trial to study AEROSURF administered to premature infants receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone.  The phase 2b trial is a global trial with clinical sites in North America, Europe and Latin America.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.

For more information, please visit the Company’s website at www.windtreetx.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties include those risks related to Windtree’s aerosolized KL4 surfactant development programs, including for AEROSURF, which may involve time-consuming and expensive clinical trials that may be subject to potentially significant delays or regulatory holds, or fail; risks related to the development of aerosol delivery systems (ADS) and related components; risks related to the manufacture by contract manufacturers or suppliers of drug products, drug substances, ADS and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including those of the U.S. Food and Drug Administration or other regulatory authorities that may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of Windtree’s products; and other risks and uncertainties described in Windtree’s filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

$SAEX Receipt of #Alaska #TaxCredit Certificates, $15M Loan Facility Unlock

HOUSTON, Oct. 24, 2016 — SAExploration Holdings, Inc. (NASDAQ:SAEX), or SAE, today announced that it has received approximately $24.4 million of tax credit certificates from the state of Alaska’s Department of Revenue. SAE further announced that as a result of receiving these tax credit certificates, and having substantially satisfied the conditional requirements under its senior term loan facility (the “Senior Loan Facility”), it has been granted access to the remaining $15.0 million of funding available under its Senior Loan Facility.

Jeff Hastings, Chairman and CEO of SAE, commented, “We are very pleased that we have begun to receive tax credit certificates from the State of Alaska sooner than expected and access to the remaining $15.0 million under our Senior Loan Facility ensures our ability to progress through the receipt and monetization of the remaining tax credits. We believe the value that can ultimately be derived from these tax credit certificates, and those yet to be issued, will be highly accretive to the company and to our stockholders.”

While some applications for tax credit certificates are still being processed by the State of Alaska, and certain remaining applications cannot be filed until after January 1, 2017, SAE currently expects to receive an additional $60.5 million of tax credit certificates from the State of Alaska over the next twelve months. While the method, terms and conditions are not certain, the company remains optimistic that it will be able to ultimately monetize a significant portion of its tax credit certificates absent material changes in Alaskan laws and further believes this process could begin before the end of this year. Any amounts received for the tax credit certificates will be applied towards the company’s outstanding accounts receivable. Consistent with the company’s past disclosure practices, however, SAE does not intend to disclose the monetization of any of its tax credit certificates, outside of its customary disclosures made in its periodic filings with the SEC.

Under the terms of SAE’s recently completed comprehensive restructuring, receipt of certificates evidencing Alaskan tax credits in excess of $25.0 million was a condition precedent to the advance of the remaining $15.0 million available under the Senior Loan Facility. Having substantially satisfied this requirement by receiving $24.4 million, or approximately 98%, of the required $25.0 million in face value of tax credit certificates, on October 24, 2016, a majority of the lenders under the Senior Loan Facility entered into Amendment No.1 to the Senior Loan Facility agreement, which waived the $25.0 million requirement, thereby granting SAE access to the remaining $15.0 million.

About SAExploration Holdings, Inc. 

SAE is an internationally-focused oilfield services company offering a full range of vertically-integrated seismic data acquisition and logistical support services in remote and complex environments throughout Alaska, Canada, South America and Southeast Asia. In addition to the acquisition of 2D, 3D, time-lapse 4D and multi-component seismic data on land, in transition zones and offshore in depths reaching 3,000 meters, SAE offers a full suite of logistical support and in-field data processing services, such as program design, planning and permitting, camp services and infrastructure, surveying, drilling, environmental assessment and reclamation and community relations. SAE operates crews around the world, performing major projects for its blue-chip customer base, which includes major integrated oil companies, national oil companies and large independent oil and gas exploration companies. Operations are supported through a multi-national presence in Houston, Alaska, Canada, Peru, Colombia, Bolivia, Brazil, New Zealand and Malaysia. For more information, please visit SAE’s website at www.saexploration.com.

The information in SAE’s website is not, and shall not be deemed to be, a part of this notice or incorporated in filings SAE makes with the Securities and Exchange Commission.

Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws with respect to SAE. These statements can be identified by the use of words or phrases such as “expects,” “estimates,” “projects,” “budgets,” “forecasts,” “anticipates,” “intends,” “plans,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions. These forward-looking statements include statements regarding SAE’s financial condition, results of operations and business and SAE’s expectations or beliefs concerning future periods and possible future events. These statements are subject to significant known and unknown risks and uncertainties that could cause actual results to differ materially from those stated in, and implied by, this press release. Risks and uncertainties that could cause actual results to vary materially from SAE’s expectations are described under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in SAE’s Form 10-Q filed on August 12, 2016, for the period ended June 30, 2016. Except as required by applicable law, SAE is not under any obligation to, and expressly disclaims any obligation to, update or alter its forward looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Contact

SAExploration Holdings, Inc.
Ryan Abney
Vice President, Capital Markets & Investor Relations
(281) 258-4409
rabney@saexploration.com

$MBVT & $CBU Announce #Merger Agreement

Community Bank System, Inc. (“Community Bank System”) (NYSE: CBU) and Merchants Bancshares, Inc. (“Merchants Bancshares”) (NASDAQ: MBVT) today announced that they have entered into a definitive agreement under which Community Bank System will acquire Merchants Bancshares, parent company of Merchants Bank in a cash and stock transaction for total consideration valued at approximately $304 million. The transaction has been unanimously approved by the boards of directors of both companies.

Merchants Bancshares is the largest statewide independent bank in Vermont, with total assets of nearly $1.9 billion, deposits of $1.5 billion and 32 banking offices. Additionally, Merchants is the third largest institution by deposit market share in Vermont, with a growing presence in Western Massachusetts. The combination will provide natural market extension for both institutions, joining two high-quality, low-risk franchises with long histories of service to their customers and communities.

Under the terms of the agreement, shareholders of Merchants Bancshares will have the option to receive, at their election, consideration per share equal to (i) 0.963 shares of Community Bank System common stock, (ii) $40.00 in cash or (iii) the combination of 0.6741 shares of Community Bank System common stock and $12.00 in cash, subject to an overall proration to 70% stock and 30% cash. The cash and stock consideration would be equivalent to $44.02 for each share of Merchants Bancshares common stock based upon the closing price of Community Bank System common stock as of October 21, 2016. The transaction is intended to qualify as a reorganization for federal income tax purposes, and as a result, the receipt of Community Bank System common stock by shareholders of Merchants Bancshares is expected to be tax-free.

“We are very excited to be partnering with Merchants Bank, extending our footprint into the attractive Vermont and Western Massachusetts markets,” said Community Bank System President & Chief Executive Officer Mark E. Tryniski. “Merchants Bank has an impressive history of service to its customers, its communities and its shareholders. More importantly, the organizational values of Merchants Bank, and its people, align very well with those of Community Bank. We are delighted to welcome the Merchants team to the Community Bank organization and look forward to the future of the combined company. We are also pleased that Geoffrey Hesslink, President & Chief Executive Officer of Merchants Bank, will become the New England Regional President of our combined organization.”

Geoffrey R. Hesslink, President and Chief Executive Officer of Merchants Bancshares commented, “We are proud to become part of a long standing, solid and complementary franchise like Community Bank. We will continue to provide our highly personalized experience to our customers, while providing them with an expanded set of products and services as a larger organization. We look forward to working closely with Community Bank System to complete the combination.”

Upon completion of the transaction, the combined company will fully absorb the cost of crossing $10 billion in assets, while providing earnings accretion for Community Bank System shareholders. Community Bank System expects the transaction to be approximately $0.10 per share accretive to 2018 GAAP earnings ($0.17 excluding the impact of crossing $10 billion in assets) and $0.15 per share accretive to 2018 cash earnings ($0.22 excluding the impact of crossing $10 billion in assets). Community Bank System intends to donate $500,000 to the Merchants Bank Foundation following the completion of the merger to further strengthen the support of the communities Merchants serves.

The merger agreement provides for two directors from Merchants Bancshares to be added to the Board of Directors of Community Bank System. The merger is expected to close in the second quarter of 2017 and is subject to customary closing conditions, including approval by the shareholders of Merchants Bancshares and required regulatory approvals.

RBC Capital Markets, LLC acted as exclusive financial advisor to Community Bank System and Cadwalader, Wickersham & Taft LLP acted as its legal advisor. Piper Jaffray & Co. acted as exclusive financial advisor to Merchants Bancshares and Goodwin Procter LLP acted as its legal advisor.

Community Bank System will host a conference call at 11 am (ET) on Tuesday, October 25, 2016 to discuss its third quarter 2016 financial results and the combination with Merchants Bancshares. The conference call can be accessed at 888-503-8171 using the conference ID code 5675553. Investors may also listen live via the Internet at: http://www.webcaster4.com/Webcast/Page/995/17761.

About Community Bank System, Inc.

Community Bank System, Inc. operates more than 200 customer facilities across Upstate New York and Northeastern Pennsylvania through its banking subsidiary, Community Bank, N.A. With assets of approximately $8.7 billion, the DeWitt, N.Y. headquartered company is among the country’s 150 largest financial institutions. In addition to a full range of retail and business banking services, the Company offers comprehensive financial planning, insurance and wealth management services through its’ Community Bank Wealth Management Group and OneGroup NY, Inc. operating subsidiaries. The Company’s Benefit Plans Administrative Services, Inc. subsidiary is a leading provider of employee benefits administration, trust services, and actuarial and consulting services to customers on a national scale. Community Bank System, Inc. is listed on the New York Stock Exchange and the Company’s stock trades under the symbol CBU. For more information about Community Bank visit www.communitybankna.com or http://ir.communitybanksystem.com.

About Merchants Bancshares, Inc.

Merchants Bancshares, Inc. reported total assets at June 30, 2016 of approximately $1.9 billion. Merchants Bancshares, Inc. is the holding company for Merchants Bank. The bank’s business, municipal, consumer, and investment customers enjoy personalized relationships, sophisticated online and mobile banking options, with 31 branches in Vermont and 1 location in Massachusetts, operating as NUVO, a division of Merchants Bank. Merchants Bancshares, Inc. is listed on the NASDAQ Stock Market and trades under the symbol MBVT. For more information about Merchants Bank visit www.mbvt.com.

Additional Information about the Merger

In connection with the proposed merger, Community Bank System, Inc. will file with the Securities and Exchange Commission (SEC) a Registration Statement on Form S-4 that will include a prospectus of Community Bank System, Inc. and a proxy statement of Merchants Bancshares, Inc., as well as other relevant documents concerning the proposed transaction. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. Stockholders of Merchants Bancshares, Inc. are urged to read the registration statement and proxy statement/prospectus and the other relevant materials filed with the SEC when they become available because they will contain important information about the proposed transaction.

A free copy of the proxy statement/prospectus, when available, as well as other filings containing information about Merchants Bancshares, Inc. and Community Bank System, Inc., may be obtained at the SEC’s Internet site (http://www.sec.gov). You will also be able to obtain these documents, when available, free of charge from Merchants Bancshares, Inc. at http://www.mbvt.com/ under the heading “Investor Relations” and then “SEC Filings” or from Community Bank System, Inc. by accessing its website at www.communitybankna.com under the heading of “Investor Relations” and then “SEC Filings & Annual Report.” Copies of the proxy statement/prospectus can also be obtained, free of charge and when available, by directing a request to Merchants Bancshares, Inc., P.O. Box 1009, Burlington, Vermont 05402, Attention: Investor Relations, Telephone: (900) 322-5222 or to Community Bank System, Inc., 5790 Widewaters Parkway, DeWitt, New York 13214, Attention: Investor Relations, Telephone: (315) 445-2282.

Merchants Bancshares, Inc. and Community Bank System, Inc. and certain of their respective directors and executive officers may be deemed to participate in the solicitation of proxies from the stockholders of Merchants Bancshares, Inc. in connection with the proposed merger. Information about the directors and executive officers of Merchants Bancshares, Inc. and their ownership of Merchants Bancshares, Inc. common stock is set forth in the proxy statement for its 2016 annual meeting of stockholders, as filed with the SEC on Schedule 14A on April 15, 2016. Information about the directors and executive officers of Community Bank System, Inc. and their ownership of Community Bank System, Inc. common stock is set forth in the proxy statement for its 2016 annual meeting of shareholders, as filed with the SEC on Schedule 14A on April 1, 2016. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the proxy statement/prospectus regarding the proposed merger when it becomes available. Free copies of this document when available may be obtained as described in the preceding paragraph.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of the words “will,” “anticipate,” “expect,” “intend,” “estimate,” “target,” and words of similar import. Forward-looking statements are not historical facts but instead express only management’s beliefs regarding future results or events, many of which, by their nature, are inherently uncertain and outside of management’s control. The following factors, among others listed in the Companies’ Form 10-K filings, could cause the actual results of the Companies’ operations to differ materially from the Companies’ expectations: failure to obtain the approval of the shareholders of Merchants Bancshares in connection with the merger; the timing to consummate the proposed merger; the risk that a condition to closing of the proposed merger may not be satisfied; the risk that a regulatory approval that may be required for the proposed merger is not obtained or is obtained subject to conditions that are not anticipated; the parties’ ability to achieve the synergies and value creation contemplated by the proposed merger; the parties’ ability to successfully integrate operations in the proposed merger; the effect of the announcement of the proposed merger on the ability of Merchants Bancshares to maintain relationships with its key partners, customers and employees, and on its operating results and business generally; competition; changes in economic conditions, interest rates and financial markets; and changes in legislation or regulatory requirements. The Companies do not assume any duty to update forward-looking statements.

$UNIS Announces 2016 #10K, #SEC #Filing Concurrence

– Company Now Current with SEC Filings – Internal Investigation Complete – Business Restructured to Prioritize Wearable Injector Customer Programs – Cost Reduction Measures Implemented – Amgen Accelerates Purchase of Initial $10 Million from $15 Million Convertible Note – Investor Conference Call Scheduled for Wednesday, November 2 at 4:30 p.m. ET

YORK, Pa., Oct. 24, 2016  — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS; ASX: UNS) today announced that it has filed its Annual Report on Form 10-K for fiscal year 2016. In addition, the Company filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 along with (i) an amendment to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015; (ii) an amendment to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015; and (iii) an amendment to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2015.

The Company also announced the completion of the internal investigation, the accelerated purchase by Amgen, Inc. of $10 million of a senior secured convertible note, and provided an update on the restructuring of its business to prioritize key wearable injector customer programs.

The Company will hold an investor conference call on Wednesday, November 2, 2016 at 4:30 p.m. ET.

Investigation Complete

Unilife has completed its investigation into violations of the Company’s policies and procedures and possible violations of law and regulation by the Company’s former Chief Executive Officer, Alan Shortall, whose employment with the Company ceased on March 11, 2016, and its former Chairman, Jim Bosnjak, who resigned from the Company’s Board of Directors on August 24, 2015.

The Company previously announced on July 28, 2016 that the investigation was substantially complete and summarized the results in its Current Report on Form 8-K filed with Securities and Exchange Commission on such date, including that the investigation had not identified any material financial loss to the Company. The investigation is now complete and has not identified any additional financial loss other than was already identified in the July 28, 2016 Form 8-K referenced above. Additional information regarding the findings of this investigation is available in the Company’s Annual Report on Form 10-K filed today.

The Company today filed its Annual Report on Form 10-K for fiscal year 2016 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016, the filings of which had been delayed as a result of the investigation.  In addition, the Company today filed amendments to the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended September 30, 2015 and December 31, 2015 and an amendment to the Company’s Annual Report on Form 10-K for fiscal year 2015 to correct immaterial errors in the previously reported financial statements and to disclose certain material weaknesses in the Company’s internal control over financial reporting and disclosure controls and procedures.

Wearable Injector Program

Unilife continues to focus on its targeted growth strategy of prioritizing active wearable injector programs with key pharmaceutical customers including Amgen, Sanofi, and MedImmune, the global biologics research and development arm of AstraZeneca. This strategy is expected to improve operating efficiencies and better position the Company to take advantage of commercial opportunities within the fast-growing market for wearable injectors, where it has industry-leading proprietary technology and technical expertise.

John Ryan, Unilife’s President and Chief Executive Officer, commented, “Unilife has brought together an industry-leading portfolio of wearable injectors, a strong base of customer programs, a talented team of innovative engineers, and a disciplined and focused leadership group. We continue to be encouraged by the commitment of our strategic partners and industry suppliers as we focus on bringing these products to market with our customers’ therapies.

Mr. Ryan continued, “We are pleased to have the internal investigation and related delay in our securities filings behind us so that we can now fully focus on executing on our wearable injector-focused strategy.  We are building an organization on a foundation of integrity, accountability, and operational discipline. We have implemented rigorous operating practices to reduce cash burn, and we have the right pieces in place to build value for shareholders, customers and partners.”

Update on Cost Reduction Measures

Unilife has implemented comprehensive cost reduction measures as it focuses operations on the programs of key strategic customers. As part of this disciplined approach toward resource allocation and expense management, the Company has reduced its workforce to approximately 140 employees and has sublet a significant portion of its office space in King of Prussia, PA.

Mr. Ryan commented, “We now have a focused and engaged team executing on wearable injector customer programs, with continuing innovation in our industry-leading wearable injector technology. We look forward to discussing our cost reduction efforts and cash burn expectations on next week’s conference call.”

Amgen Note Purchase

Unilife today announced that Amgen has purchased a $10 million senior secured convertible note. This transaction is an acceleration of a portion of the $15 million senior secured convertible note that was originally contemplated to be purchased in January 2017 under the terms of the strategic collaboration announced in February 2016. The $5 million balance of the $15 million convertible note is contemplated to be purchased by Amgen in January 2017, with an additional $10 million senior secured convertible note contemplated to be purchased in January 2018, in each case, subject to the terms of the strategic collaboration announced in February 2016.

The terms of the note purchased are discussed further in a Current Report on a Form 8-K filed by the Company today.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. EDT on Wednesday, November 2, 2016 (Thursday, November 3, 2016 at 7:30 a.m. AEDT) to provide a business update and to review the Company’s financial results and future outlook. The conference call will be broadcast over the Internet as a “live” listen-only webcast. An archive of the webcast will be available for 30 days after the call. To listen, go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife has a portfolio of innovative, differentiated products with a primary focus on wearable injectors. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife’s global headquarters and manufacturing facilities are located in York, PA.  For more information, visit www.unilife.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K, those described in the “Risk Factors” set forth in Unilife’s prospectus supplement, dated as of and filed with the U.S. Securities and Exchange Commission on February 22, 2016, those described from time to time in other reports which we file with the U.S. Securities and Exchange Commission, and other risks and uncertainties including, without limitation: that Amgen may not purchase the remaining $5 million balance of the senior secured convertible note in January 2017 or the additional $10 million senior secured convertible note in January 2018; and that the Company’s focus on wearable injector programs with key pharmaceutical customers may not improve its operating efficiencies or better position the Company to take advantage of commercial opportunities.

General: UNIS-G

Investor Contact (US):
Jeremy Feffer
Unilife Corporation
+1-717-384-3450
investors@unilife.com

Investor Contact (Australia):
Jeff Carter
Unilife Corporation
+61 2 8346 6500

$VIAB Celebrates the Power of Stories in Its #2016SocialImpactReview

Viacom Inc. (NASDAQ:VIAB, VIA) yesterday released its 2016 Social Impact Review that details how the company amplified the unique voices of its audiences and employees to create positive change throughout 2015. The Power of Stories is the product of Viacommunity, the umbrella arm of Viacom’s corporate social responsibility program, which unveiled the report at a Social Impact Fair in its New York City headquarters that featured a musical performance by award-winning R&B artist Mario.

“Viacom continues to lead the way in delivering positive social impact through the power of entertainment and through the passion of our fans whose stories inspire us to act,” said Ali Jannello Tuck, VP of Corporate Social Responsibility at Viacom. “2015 showcased the incredible work of our brands to educate and mobilize viewers globally on issues that matter most to them: domestic violence and sexual assault, gender and racial equality, reproductive health, childhood education, veteran care, and environmental protection, among many others.”

To address society’s biggest challenges, Viacommunity focuses its efforts on six areas that align with the United Nation’s Sustainable Development Goals: building inclusive societies; pioneering social change; promoting healthy living; inspiring future generations; empowering people; and managing business responsibly.

Some examples of 2015 successes include:

• The global impact of MTV’s Staying Alive Foundation and acclaimed Nigerian television series MTV Shuga, which together form a revolutionary mass-media campaign on sexual health. The foundation raised more than $2 million for ongoing HIV/AIDS projects, while female viewers of Shuga experienced a 68% reduction in chlamydia infections, according to the World Bank. In the U.S., MTV’s airing of White People, a groundbreaking documentary that examines race in America from the viewpoint of white Millennials, has helped provoke a national conversation about the realities of white privilege. Likewise, MTV’s Look Different Campaign created a gender-focused implicit bias quiz on Women’s Equality Day to address gender bias, and released an eye-opening study that shows how young people often have difficulty identifying issues related to gender equality, such as equal pay and “slut shaming.”

• The launch of Logo’s documentary films division to elevate stories that capture LGBT life and culture. Logo released five award-winning films including Matt Shepard is a Friend of Mine, which earned the network a Daytime Emmy Award. During the Supreme Court’s landmark ruling on same-sex marriage, Logo’s #All50 campaign allowed people to share personal stories and support for marriage equality. Additionally, the 2015 Logo Trailblazer Honors, which celebrates pioneers at the forefront of the fight for equality, was the largest televised Pride month event; there, it recognized activist Arsham Parsi for his work to aid LGBT communities in Iran.

• Viacom’s partnership with WITNESS, a global human rights organization, on a powerful public service announcement campaign in New York City. “WITNESS the Power of Story” used video projection and social media at locations across the city to highlight issues of gender, race, sexuality, among others, and to call attention to Viacommunity’s biggest campaigns. Viacom – through its NO MORE partnership with the Joyful Heart Foundation – also teamed up with Verizon to develop a TV spot that raised awareness of the 6,000 victims of domestic violence turned away from shelters every day. Viacom Says NO MORE PSAs also continue to run across our networks, sparking important discussion about domestic abuse and sexual assault.

• Nickelodeon’s national summer tour of its “Worldwide Day of Play,” with health and wellness-themed activities that encouraged more than 20,000 kids to get out and get active. The network also launched the first-ever “Get Dirty! Challenge” called on kids to submit videos showing how they were doing their part to protect the environment, and featured eco-themed TV spots with celebrities to demonstrate environmental stewardship. Nickelodeon Spain hosted of SLIME FEST, a musical festival to raise money to combat bullying and cyberbullying, in partnership with Save the Children. And through Nickelodeon’s Helping and Leading Others (HALO) Awards, 20 charities received $100,000 to turn kids’ causes into powerful change agents for good.

• BET’s “Where Do You Do It?” PSA to educate African-American women about breast cancer and empower them to take control over their health garnered 57.8 million views. BET’s What’s At Stake, a powerful weekly web series, continued to focus on the most critical issues affecting young people of color in America. BET Youth Experience invited 50 high school students to learn what it takes to put on a music festival as part of the network’s commitment to education and career development in the entertainment industry. And its Next Level website aided some 600,000 students in choosing the right schools and making career plans.

• SPIKE’s Veterans Operation Wellness (VOW) Guinness World Records™ Pull-Ups Challenge, which raised awareness of veterans’ issues including post-traumatic stress disorder and inspired vets to commit to their health. VOW works with dozens of veterans organizations to assist veterans lead healthier lives through training, exercise, better diet and engagement in their communities.

• VH1 Save the Music Foundation raised $2.3 million for 2,000 schools across the country in 2015, and put $1.4 million worth of musical instruments in students’ hands, with the goal of ensuring that every public school kid in America gets the benefit of music education.

• The advancement of CMT’s Empowering Education Community College Initiative, which assists people in rural communities to build the skills they need to thrive in today’s changing economy. CMT has hosted 20 free events at community and technical colleges across the country, using music and storytelling to encourage attendees to consider higher education opportunities.

• Paramount’s Got Your 6 Storyteller Awards, which spotlighted the talents of some of the best and brightest military veterans, and the studio’s volunteers hosted more than 400 veterans at a barbeque at the VA Greater Los Angeles Healthcare System. 250 Paramount volunteers also participated in the 2015 AIDS Walk to raise money for HIV/AIDS research – its largest team to date.

• Comedy Central Latin America’s launch of its Stand Up Mobile campaign that encourages companies and parents to promote a safer online environment for children. As part of the award-winning campaign, three stand-up routines featuring renowned Latin American comedians were broadcasted weekly as PSAs to shed light on this important topic.

To read the full report, please visit www.viacommunity.com

About Viacom

Viacom is home to premier global media brands that create compelling television programs, motion pictures, short-form content, apps, games, consumer products, social media experiences, and other entertainment content for audiences in 180 countries. Viacom’s media networks, including Nickelodeon, Comedy Central, MTV, VH1, Spike, BET, CMT, TV Land, Nick at Nite, Nick Jr., Channel 5 (UK), Logo, Nicktoons, TeenNick and Paramount Channel, reach over 3.8 billion cumulative television subscribers worldwide. Paramount Pictures is a major global producer and distributor of filmed entertainment.

For more information about Viacom and its businesses, visit www.viacom.com. Keep up with Viacom news by following Viacom’s blog at blog.viacom.com and Twitter feed at www.twitter.com/viacom.

Press:
David Lieberson, 212-593-5894
david.lieberson@finnpartners.com

$AIMC to #Acquire #GKN’s #Stromag Business

Provides Complementary Products, End Markets and Geographies

Expected to be Accretive in First 12 Months of Operations

BRAINTREE, Mass., Oct. 21, 2016 — Altra Industrial Motion Corp. (NASDAQ:AIMC), a global manufacturer and marketer of electromechanical power transmission and motion control products, today announced that it intends to acquire the Stromag business from GKN plc.  Stromag generated approximately 131 million euros in revenue in 2015, and the acquisition is anticipated to be accretive to Altra’s earnings in 2017, excluding any one-time or acquisition-related costs.

The acquisition cost comprises the assumption of debt totaling approximately 14 million euros and a cash consideration, payable at closing, of approximately 184 million euros and is subject to normal adjustments in working capital and other reconciling items

“The acquisition of Stromag will provide Altra with complementary products, greater presence in key geographic regions, and penetration into new growth end markets,” said Carl Christenson, Altra’s Chairman and CEO. “Stromag possesses a very strong brand reputation and its highly engineered clutches, brakes, torsional couplings and limit switches serve as excellent product extensions for Altra. We see outstanding opportunities for our two sales forces to cross sell products into new markets and we are excited to utilize Stromag’s resources to further expand Altra’s global customer coverage.”

“The combination also provides compelling opportunities to leverage cost synergies through Altra’s supply chain and Operational Excellence programs. Stromag brings a strong and experienced management team, and we welcome them and the more than 700 Stromag employees to Altra.”

Stromag is a market-leader with a strong technology base and a heritage of providing tailored engineered solutions for its customers. Its core products include an array of clutches and brakes, flexible couplings, limit switches and friction discs.  Stromag serves the agricultural equipment, construction, crane & hoist, marine, metal processing, renewable energy and general industrial markets. Founded in 1932, the business is headquartered in Unna, Germany and has operations in Germany, France, the U.S., the UK, Brazil, India and China.

The closing of the transaction is expected to take place during the first quarter of 2017 and is subject to customary information and consultation processes with the Stromag Works Council and trade unions as well as customary closing conditions including the receipt of anti-trust approvals.

Altra will discuss the intended acquisition of Stromag during Altra’s Third Quarter 2016 Investor Conference Call scheduled for Friday, October 21, 2016 at 10:00 a.m. ET.  The public is invited to listen to the conference call by dialing 877-407-8293 domestically or 201-689-8349 for international access and asking to participate in the ALTRA conference call.

About Altra Industrial Motion Corp.

Altra Industrial Motion Corp., through its subsidiaries, is a leading global designer, producer and marketer of a wide range of electromechanical power transmission and motion control products. The Company brings together strong brands covering over 40 product lines with production facilities in eleven countries. Altra’s leading brands include Ameridrives Couplings, Bauer Gear Motor, Bibby Turboflex, Boston Gear, Delroyd Worm Gear, Formsprag Clutch, Guardian Couplings, Huco, Industrial Clutch, Inertia Dynamics, Kilian Manufacturing, Lamiflex Couplings, Marland Clutch, Matrix, Nuttall Gear, Stieber Clutch, Svendborg Brakes, TB Wood’s, Twiflex, Warner Electric, Warner Linear, and Wichita Clutch. [AIMC-G]

All statements, other than statements of historical fact included in this release are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Forward-looking statements can generally be identified by phrases such as “believes,” “expects,” “potential,” “continues,” “may,” “should,” “seeks,” “predicts,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “could,” “designed”, “should be,” and other similar expressions that denote expectations of future or conditional events rather than statements of fact. Forward-looking statements also may relate to strategies, plans and objectives for, and potential results of, future operations, financial results, financial condition, business prospects, growth strategy and liquidity, and are based upon financial data, market assumptions and management’s current business plans and beliefs or current estimates of future results or trends available only as of the time the statements are made, which may become out of date or incomplete. Forward-looking statements are inherently uncertain, and investors must recognize that events could differ significantly from our expectations. These statements include, but may not be limited to, those relating to the Company’s progress on corporate initiatives, including its supply chain management initiative and Operational Excellence program and expectations regarding opportunities to leverage cost synergies through the initiatives as a result of the Stromag acquisition, the Company’s views and assessment of economic conditions, the Company’s expectations with respect to sales, the Company’s progress on executing its acquisition and organic growth strategies, the Company’s expectations regarding complementary products, greater presence in key geographic regions and penetration into new growth end markets as a result of the Stromag acquisition, the Company’s expectations regarding opportunities for multiple sales forces to cross sell products into new markets as a result of the Stromag acquisition, the Company’s progress and future plans on implementing and pursuing consolidation and cost reduction activities and the cost savings associated therewith, the timing of closing the Stromag acquisition and the Company’s expectations regarding the extent and timing of the accretive impact of the Stromag acquisition on earnings.

In addition to the risks and uncertainties noted in this release, there are certain factors that could cause actual results to differ materially from those anticipated by some of the statements made. These include: (1) competitive pressures, (2) changes in economic conditions in the United States and abroad and the cyclical nature of our markets, (3) loss of distributors, (4) the ability to develop new products and respond to customer needs, (5) risks associated with international operations, including currency risks, (6) accuracy of estimated forecasts of OEM customers and the impact of the current global economic environment on our customers, (7) risks associated with a disruption to our supply chain, (8) fluctuations in the costs of raw materials used in our products, (9) product liability claims, (10) work stoppages and other labor issues, (11) changes in employment, environmental, tax and other laws and changes in the enforcement of laws, (12) loss of key management and other personnel, (13) risks associated with compliance with environmental laws, (14) the ability to successfully execute, manage and integrate key acquisitions and mergers, (15) failure to obtain or protect intellectual property rights, (16) risks associated with impairment of goodwill or intangibles assets, (17) failure of operating equipment or information technology infrastructure, (18) risks associated with our debt leverage and operating covenants under our debt instruments, (19) risks associated with restrictions contained in our Convertible Notes and Credit Facility, (20) risks associated with compliance with tax laws, (21) risks associated with the global recession and volatility and disruption in the global financial markets, (22) risks associated with implementation of our ERP system, (23) risks associated with the Svendborg, Guardian and Stromag acquisitions and integration and other acquisitions, including but not limited to risks related to the integration of Stromag’s sales force, management team and other employees and failure to close the Stromag acquisition, (24) risks associated with the closure of the Company’s manufacturing facility in Changzhou, China, (25) risks associated with certain minimum purchase agreements we have with suppliers, (26) risks associated with our exposure to variable interest rates and foreign currency exchange rates, (27) risks associated with interest rate swap contracts, (28) risks associated with the potential dilution of our common stock as a result of our convertible notes, (29) risks associated with our exposure to renewable energy markets, (30) risks related to regulations regarding conflict minerals, (31) risks related to restructuring and plant consolidations, (32) risk associated with the UK vote to leave the European Union and (33) other risks, uncertainties and other factors described in the Company’s quarterly reports on Form 10-Q and annual reports on Form 10-K and in the Company’s other filings with the U.S. Securities and Exchange Commission (SEC) or in materials incorporated therein by reference. Except as required by applicable law, Altra Industrial Motion Corp. does not intend to, update or alter its forward looking statements, whether as a result of new information, future events or otherwise.

Contact:
Altra Industrial Motion Corp.
Christian Storch, Chief Financial Officer
(781) 917-0541
christian.storch@altramotion.com

$CNFR Preliminary #Estimate of Catastrophe #Losses from #HurricaneMatthew

BIRMINGHAM, Mich., Oct. 21, 2016  — Conifer Holdings, Inc. (Nasdaq:CNFR) (“Conifer” or the “Company”) announced today an update regarding Hurricane Matthew, which impacted the state of Florida and Eastern Coast of the United States in October.

While the ultimate cost and impact on the Company’s financial results cannot be determined with exact certainty at this time, the Company currently estimates that its aggregate gross liabilities as a result of Hurricane Matthew will be approximately $1.85 million.  The total, which will be reported in the current fourth quarter, is below the $5 million retention that is set through its existing reinsurance program.

James Petcoff, Chairman and CEO, commented, “While the impact of Hurricane Matthew was not as severe as initially predicted, we understand that our mandate is to provide a high level of customer service following storm activity.  We have, and will continue to, work closely with our agency partners and claims group to assist all of Conifer’s policyholders following the event and ensure their needs are properly met.”

About the Company
Conifer Holdings, Inc. is a Michigan-based insurance holding company formed in 2009.  Through its subsidiaries, Conifer offers insurance coverage in both specialty commercial and specialty personal product lines marketing through independent agents in all 50 states.  The Company completed its initial public offering in August 2015 and is traded on the Nasdaq Global Market (Nasdaq:CNFR).  Additional information is available on the Company’s website at www.CNFRH.com.

Forward-Looking Statement
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include Conifer’s expectations regarding premiums, earnings, its capital position, expansion, and growth strategies.  The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information.  The forward-looking statements are qualified by important factors, risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those in the forward-looking statements, including those described in our form 10-K (“Item 1A Risk Factors”) filed with the SEC on March 15, 2016 and subsequent reports filed with or furnished to the SEC.  Any forward-looking statement made by us in this report speaks only as of the date hereof or as of the date specified herein.  We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws or regulations.

For Further Information:
Jessica Gulis, 248.559.0840
ir@cnfrh.com

$JCOM #ZiffDavis to Acquire $EVDY #EverydayHealth

j2 Global, Inc. and Ziff Davis, LLC, a leading digital media company in the technology, gaming and lifestyle categories, today announced that Ziff Davis has entered into a definitive merger agreement to acquire Everyday Health, Inc. (NYSE: EVDY), a leading provider of digital health marketing and communications solutions. Under the terms of the agreement, Ziff Davis will acquire Everyday Health for $10.50 per share in cash, representing an approximate enterprise value of $465 million. Ziff Davis comprises the Digital Media Division of j2 Global, Inc.

Under the terms of the merger agreement, Ziff Davis will commence a tender offer to acquire all of the outstanding shares of Everyday Health for $10.50 per share in cash followed by a merger in which each remaining untendered share of Everyday Health common stock would be converted into the right to receive the same $10.50 cash per share consideration as in the tender offer. The transaction is conditioned upon satisfaction of the minimum tender condition, which requires that shares representing more than 50 percent of Everyday Health’s common shares be tendered, and is subject to regulatory approvals and other customary closing conditions.

Information About Forward-Looking Statements

This document contains forward-looking statements. These statements are based on j2’s estimates and assumptions and are subject to risks and uncertainties. Forward-looking statements include the information concerning j2’s possible or assumed future results of operations and the transactions contemplated by the merger agreement. Forward-looking statements also include those preceded or followed by the words “anticipates,” “believes,” “estimates,” “hopes” or similar expressions. j2’s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to the risk that the acquisition will not close when expected or at all; the risk that Ziff Davis’ business and/or Everyday Health’s business will be adversely impacted during the pendency of or following the acquisition and the risk that the operations of the two companies will not be integrated successfully. For a further list and description of these and other important risks and uncertainties that may affect j2’s future operations, see Part II, Item 1A – “Risk Factors” of the Quarterly Reports on Form 10-Q (if any) j2 has filed or will file hereafter and in Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 (together, the “Risk Factors”), and the factors discussed in the sections in j2’s Quarterly Reports on Form 10-Q entitled “Quantitative and Qualitative Disclosures About Market Risk.” Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date hereof. j2 undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements. Readers should carefully review the Risk Factors and the risk factors set forth in other documents j2 files from time to time with the United States Securities and Exchange Commission (the “SEC”).

Additional Information

The tender offer described in this communication (the “Offer”) has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Everyday Health or any other securities. This communication is for informational purposes only. The Offer is not being made to, nor will tenders be accepted from, or on behalf of, holders of shares in any jurisdiction in which the making of the tender offer or the acceptance thereof would not comply with the laws of that jurisdiction. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the SEC. The offer to purchase shares of Everyday Health common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. The tender offer statement will be filed with the SEC by Purchaser, a wholly owned subsidiary of Ziff Davis and Ziff Davis, and the solicitation/recommendation statement will be filed with the SEC by Everyday Health. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the tender offer that will be named in the tender offer statement.

About Ziff Davis, LLC

Ziff Davis, a subsidiary of j2 Global, Inc., is a leading global digital-media company operating in the technology, gaming, entertainment and lifestyle verticals. Its brands – IGN, PCMag, AskMen, Speedtest, Offers, ExtremeTech, Geek, Toolbox, TechBargains, emedia and Salesify – produce and distribute premium content across multiple platforms and devices. It delivers advertising, performance marketing and licensing solutions to thousands of clients worldwide.

About j2 Global

j2 Global, Inc. provides Internet services through two divisions: Business Cloud Services and Digital Media. The Business Cloud Services Division offers Internet fax, virtual phone, hosted email, email marketing, online backup, unified communications and CRM solutions. It markets its services principally under the brand names eFax®, eVoice®, FuseMail®, Campaigner®, KeepItSafe®, Livedrive®, Onebox®, and LiveVault®, and operates a messaging network spanning 50 countries on six continents. The Digital Media Division offers technology, gaming and lifestyle content through its digital properties, which include IGN, PCMag, AskMen, Speedtest, Offers, ExtremeTech, Geek, Toolbox, TechBargains, emedia and Salesify. As of December 31, 2015, j2 had achieved 20 consecutive fiscal years of revenue growth. For more information about j2, please visit www.j2global.com.

About Everyday Health, Inc.

Everyday Health, Inc. (NYSE: EVDY) is a leading provider of digital health marketing and communications solutions. Everyday Health attracts a large and engaged audience of consumers and healthcare professionals to its premier health and wellness properties, and utilizes its data and analytics expertise to deliver highly personalized content experiences and efficient and effective marketing and engagement solutions. Everyday Health enables consumers to manage their daily health and wellness needs, healthcare professionals to stay informed and make better decisions for their patients, and marketers, health payers and providers to communicate and engage with consumers and healthcare professionals to drive better health outcomes. Everyday Health’s content and solutions are delivered through multiple channels, including desktop, mobile web, and mobile phone and tablet applications, as well as video and social media.

$CXRX Announces CEO Transition Plan

OAKVILLE, ON, Oct. 21, 2016 – Concordia International Corp. (“Concordia” or the “Company”) (NASDAQ: CXRX) (TSX: CXR) today announced that Mark L. Thompson will step down as Chief Executive Officer of the Company following the appointment of a successor.

“Mark was our founder and successfully built Concordia into an international specialty pharmaceutical company. Under his leadership, Concordia today has a robust product pipeline and a platform that reaches patients in over 100 countries. He and the Board agreed that this would be the ideal time for a leadership change at the Company and the Board thanks him for his significant contribution over the years,” said Jordan Kupinsky, Lead Independent Director.

A search process for a new CEO is underway.

“This is an important juncture for Concordia,” continued Mr. Kupinsky. “We recently closed a very successful US$350 million debt offering and completed a strategic review of the business. With a portfolio of more than 200 products, a platform for continued international expansion, a strong commercial footprint and opportunities for organic growth, we look forward to building on our past successes.”

Mr. Thompson will also step down from the Board of Directors, where he serves as Chairman, when a successor has been appointed.

About Concordia

Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established, off-patent molecules that make up more than 1,300 SKUs. Concordia also markets orphan drugs through its Orphan Drugs Division, consisting of Photofrin® for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications.

Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.

Notice regarding forward-looking statements and information:

This press release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to, the appointment of a successor chief executive officer and Chairman, Concordia’s platform for continued international expansion, Concordia’s strong commercial footprint, opportunities for organic growth, Concordia building on past successes and other factors. Often, but not always, forward-looking statements and forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Concordia’s management, and are based on assumptions and subject to risks and uncertainties. Although Concordia’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to the inability to find and appoint a successor chief executive officer and/or Chairman, Concordia’s securities, risks associated with developing new product indications, increased indebtedness and leverage, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, the inability to repay debt and/or satisfy future obligations (including, without limitation, earn out obligations), risks associated with Concordia’s outstanding debt, risks associated with the geographic markets in which Concordia operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Concordia’s products to treat certain diseases, the pharmaceutical industry and the regulation thereof, regulatory investigations, the failure to comply with applicable laws, risks relating to distribution arrangements, possible failure to realize the anticipated benefits of acquisitions and/or product launches, risks associated with the integration of assets and businesses into Concordia’s business, product launches, the inability to launch products, the fact that historical and projected financial information may not be representative of Concordia’s future results, the failure to obtain regulatory approvals, economic factors, market conditions, acquisition opportunities, risks associated with the acquisition and/or launch of pharmaceutical products, risks regarding clinical trials and/or patient enrollment into clinical trials, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Concordia’s niche, hard-to-make products), general economic and stock market conditions, risks associated with the United Kingdom’s exit from the European Union (including, without limitation, risks associated with regulatory changes in the pharmaceutical industry, changes in cross-border tariff and cost structures and the loss of access to the European Union global trade markets), risks related to patent infringement actions, the loss of intellectual property rights, risks and uncertainties detailed from time to time in Concordia’s filings with the Securities and Exchange Commission and the Canadian Securities Administrators and many other factors beyond the control of Concordia.  Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and forward-looking information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement or forward-looking information, whether as a result of new information, future events, or otherwise.

$CRNT Selected as the Primary Wireless Backhaul Supplier for a Tier 1 US Operator

Initial orders for FibeAir IP-20 Platform of over $4 million received in Q4

LITTLE FALLS, New Jersey, October 20, 2016 —

Ceragon Networks Ltd. (NASDAQ: CRNT), the #1 wireless backhaul specialist, today announced that a Tier 1 US operator selected Ceragon as its primary wireless backhaul supplier to support its network densification and optimization strategy. This strategy is aimed at improving subscriber experience and continually meeting the growing demand for capacity. Initial orders for the FibeAir IP-20 Platform of over $4 million have been received in Q4.

Ceragon’s FibeAir IP-20 Platform, with its unique multicore technology, offers the operator a highly innovative, quick rollout with the scalability to increase capacity as its network expands and densifies over time. “We are delighted to partner with the operator to support its network strategy,” said Ira Palti, president and CEO of Ceragon. “Our IP-20 Platform is highly deployed worldwide and is second-to-none in the industry in terms of generating value to our customers through its high capacity, field-proven reliability and its versatility for use in any deployment scenario. We look forward to a successful long term partnership.”

About Ceragon Networks Ltd.

Ceragon Networks Ltd. (NASDAQ: CRNT) is the world’s #1 wireless backhaul specialist. We help operators and other service providers worldwide increase operational efficiency and enhance end customers’ quality of experience with innovative wireless backhaul solutions. Our customers include wireless service providers, public safety organizations, government agencies and utility companies, which use our solutions to deliver 4G, mission-critical multimedia services and other applications at high reliability and speed. Ceragon’s unique multicore technology provides a highly reliable, high-capacity 4G wireless backhaul with minimal use of spectrum, power and other resources. It enables increased productivity, as well as simple and quick network modernization. We deliver a range of professional services that ensure efficient network rollout and optimization to achieve the highest value for our customers. Our solutions are deployed by more than 460 service providers, as well as hundreds of private network owners, in more than 130 countries.

Join the discussion
http://www.linkedin.com/companies/14470
https://www.facebook.com/ceragonnetworks/
https://twitter.com/Ceragon
https://www.youtube.com/user/CeragonNetworks?feature=mhum
http://blog.ceragon.com/blog

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON ® is a trademark of Ceragon Networks Ltd., registered in various countries. Other names mentioned are owned by their respective holders.

Safe Harbor

This press release contains statements concerning Ceragon’s future prospects that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Ceragon’s management. Examples of forward-looking statements include: projections of capital expenditures and liquidity, competitive pressures, revenues, growth prospects, product development, financial resources, restructuring costs, cost savings and other financial matters. You may identify these and other forward-looking statements by the use of words such as “may,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “expects,” “intends,” “potential” or the negative of such terms, or other comparable terminology. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks associated with a further decline in revenues beyond Ceragon‘s expectations, the risk that Ceragon‘s expectations regarding future profitability will not materialize; the risk that Ceragon will not achieve the benefits it expects from its expense reduction and profit enhancement programs; the risk that Ceragon will not continue to comply with the financial or other covenants in its agreements with its lenders; risks associated with doing business in Latin America in general and in Brazil in particular, including currency export controls and recent economic concerns; risks relating to the concentration of our business in India, Africa, and in developing nations, including political, economic and regulatory risks from doing business in those regions; the risk of significant expenses in connection with potential contingent tax liability; and other risks and uncertainties detailed from time to time in Ceragon’s Annual Report on Form 20-F and Ceragon’s other filings with the Securities and Exchange Commission, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

Media Contact:
Matthew Krieger
GK Public Relations
Tel: + 914-768-4219
matthew@gkpr.com

Company Contact:
Tanya Solomon
Ceragon Networks
Tel: +972-3-543-1163
tanyas@ceragon.com

Investor Contact:
Claudia Gatlin
Tel. +1-(212)-830-9080
claudiag@ceragon.com

$GST Announces #Oklahoma Development Agreement in Kingfisher County

HOUSTON, Oct. 20, 2016  — Gastar Exploration Inc. (NYSE MKT: GST) (“Gastar” or the “Company”) announced that it has executed a definitive agreement with a large private global investment fund (“Investor”) to jointly develop up to 60 Gastar operated wells in the STACK Play in Kingfisher County, Oklahoma (“Development Agreement”).  The drilling program (“Drilling Program”) will target the Meramec and Osage formations within the Mississippi Lime on a contract area within three townships covering approximately 18,000 undeveloped net mineral acres under leases held by Gastar. Gastar will be the operator of all wells jointly developed under the Development Agreement.

Under the Development Agreement, the Investor will fund 90% of Gastar’s working interest portion of drilling and completion costs to initially earn 80% of Gastar’s working interest in each new well (in each case, proportionately reduced by other participating working interests in the well).  As a result, Gastar will pay 10% of its working interest portion of such costs for 20% of its original working interest in the well.

The proposed Drilling Program wells will be mutually developed in three tranches of 20 wells each.  The locations of the first 20 wells have been mutually agreed upon with 18 wells targeting the Meramec formation and two wells targeting the Osage formation.  The locations of the second tranche of 20 Drilling Program wells will be at the election of the Investor and the third tranche of 20 wells will require mutual consent.  With respect to each 20 well tranche, when the Investor has achieved an aggregate 15% internal rate of return (“IRR”) for its investment in the tranche, its interest will be reduced from 80% to 40% of Gastar’s original working interest and Gastar’s working interest increases from 20% to 60% of Gastar’s original working interest.  When a tranche IRR of 20% is achieved by the Investor, its working interest decreases to 10% and Gastar’s working interest increases to 90% of the working interest originally owned by it.  The parties to the Development Agreement can mutually agree to expand the Drilling Program’s contract area and formation focus.

Key highlights of the Development Agreement are:

• Enhances Gastar’s ability to hold acreage by production, reducing future lease renewal costs;
• Increased drilling activity allows for more rapid delineation of Gastar’s STACK acreage;
• Investor earns only an interest in the well bores drilled under the Drilling Program, with Gastar retaining all operational control and right to keep offset formation locations at its full original working interest.
• Gastar may book offsetting proved undeveloped locations at full original working interest; and
• Gastar’s 10% carried working interest and projected future reversionary interests will increase production and cash flow while reducing capital requirements.

J. Russell Porter, Gastar’s President and CEO, commented, “This Development Agreement greatly expands our ability to delineate and hold our acreage in the STACK Play without putting undue pressure on our balance sheet or requiring equity issuances in the current market. The structure of this Drilling Program, which allows us to revert to 90% of Gastar’s original interest after our partner receives a 20% return, reflects our confidence in the quality of our acreage.  We will also benefit from information garnered from the Drilling Program to develop future offset locations for our own interest.  We have already commenced drilling five of the initial 20 wells that will be included in the first tranche of the Drilling Program.  We also plan to continue to drill and complete wells apart from the Development Agreement on acreage outside of the contract area as we further explore and develop our Oklahoma acreage.”

Canadian County Property Sale

Gastar has entered into a purchase and sale agreement to sell certain non-core leasehold interests primarily in northeast Canadian County and also in southeast Kingfisher County, Oklahoma to a private third party for approximately $71.0 million (of which up to $10 million is contingent upon the satisfaction of certain conditions), subject to certain adjustments.  The transaction is expected to close on or before November 18, 2016, with a property sale effective date of August 1, 2016.

“The sale of these assets will allow us to focus on and accelerate our core STACK delineation program in northern Kingfisher and southern Garfield Counties, Oklahoma, while significantly enhancing our liquidity position,” said J. Russell Porter, Gastar’s President and CEO..  “Assuming completion of this transaction, our June 30, 2016 pro forma Mid-Continent area net acreage would be approximately 83,200 net surface acres, including acreage dedicated under our Development Agreement, with approximately 1,031 net STACK locations.”

“Upon closing of this sale, we expect to have ample liquidity to support our capital expenditure plans for the remainder of 2016 and 2017.  On a pro forma basis as of September 30, 2016, and after payment of 20% of the Canadian County net sales proceeds to reduce revolving credit facility debt, Gastar would have a cash position of approximately $102.4 million.”

The sales price includes allocated value for 19,100 net acres and current production of approximately 181 barrels of oil equivalent per day from 25 gross (11.2 net) wells, of which 32% is oil. The closing of the proposed property sale is subject to the satisfaction of customary closing conditions.

Revolving Credit Facility Amendment

Effective October 14, 2016, Gastar entered into an amendment to its revolving credit facility.  Key amendment terms include:

• Borrowing base reaffirmed at $100.0 million (the current amount outstanding under the facility) with next redetermination scheduled for November 2016;
• Revolver debt balance to be reduced by 20% of any future net sales proceeds from the sale of the Company’s South STACK acreage primarily located in Canadian County, Oklahoma;
• Minimum interest coverage ratio reduced to 0.8 to 1.0 for fourth quarter 2016 and first quarter 2017, 1.0 to 1.0 for second quarter 2017 and 2.50 to 1.0 thereafter, each as determined using adjusted EBITDA for previous four quarters; and
• Modifies provisions related to lien and asset dispositions to accommodate the Drilling Program.

About Gastar Exploration

Gastar Exploration Inc. is a pure play Mid-Continent independent energy company engaged in the exploration, development and production of oil, condensate, natural gas and natural gas liquids. Gastar’s principal business activities include the identification, acquisition, and subsequent exploration and development of oil and natural gas properties with an emphasis on unconventional reserves, such as shale resource plays. Gastar holds a concentrated acreage position in what is believed to be the core of the STACK Play, an area of central Oklahoma which is home to multiple oil and natural gas-rich reservoirs including the Meramec, Oswego, Osage, Woodford and Hunton formations. For more information, visit Gastar’s website at www.gastar.com.

Forward Looking Statements

This news release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward looking statements give our current expectations, opinion, belief or forecasts of future events and performance.  A statement identified by the use of forward looking words including “may,” “expects,” “projects,” “anticipates,” “plans,” “believes,” “estimate,” “will,” “should,” and certain of the other foregoing statements may be deemed forward-looking statements.  Although Gastar believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release.  These include risks regarding closing the sale of Gastar’s non-core assets in Canadian County, Oklahoma and in Kingfisher County, Oklahoma  the risk of receipt of the settlement funds; and other risks described in Gastar’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC, available at the SEC’s website at www.sec.gov. By issuing forward looking statements based on current expectations, opinions, views or beliefs, Gastar has no obligation and, except as required by law, is not undertaking any obligation, to update or revise these statements or provide any other information relating to such statements.

Contacts:
Gastar Exploration Inc.
J. Russell Porter, Chief Executive Officer
713-739-1800 / rporter@gastar.com

Investor Relations Counsel:
Lisa Elliott, Dennard-Lascar Associates:
713-529-6600 / lelliott@DennardLascar.com

$ALKS Positive Topline Results #FORWARD5 #ALKS5461 in #MDD

Alkermes plc (NASDAQ: ALKS) today announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The study met its prespecified primary endpoint showing treatment with ALKS 5461 significantly reduced symptoms of depression in patients with MDD compared to placebo. ALKS 5461 was generally well tolerated. The most common adverse events observed for ALKS 5461 were nausea, dizziness and fatigue. Based on these results, along with the substantial data collected to date on the efficacy and safety of ALKS 5461 for the treatment of MDD, the company plans to request a meeting with the U.S. Food and Drug Administration’s (FDA) Division of Psychiatric Products to discuss the filing strategy for this Fast Track designated medicine.

“We designed ALKS 5461 to have a novel mechanism of action for the treatment of MDD, a serious disease where new therapeutic options are highly sought after as millions of patients in the U.S. do not respond to standard courses of antidepressant therapy,” said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. “With the successful completion of the FORWARD-5 study and data from more than 1,500 patients to date, we have established a strong foundation of evidence of ALKS 5461’s clinical utility in the adjunctive treatment of major depressive disorder. With these data now in hand, we will move forward rapidly to meet with the FDA to determine the appropriate next steps toward a regulatory submission for ALKS 5461, with a goal of bringing this important new medication to patients with MDD.”

“ALKS 5461 embodies our dedication to developing novel and safe CNS medicines that address compelling unmet needs faced by large numbers of patients,” said Richard Pops, Chief Executive Officer of Alkermes. “Major depressive disorder affects millions of people and their families, and represents one of the greatest burdens of suffering and cost of any disease today. New drug development in the field is challenging and we are excited to advance ALKS 5461 in this important indication.”

In the study, ALKS 5461 2mg/2mg met the prespecified primary endpoint of significantly reducing depression scores compared to placebo, as measured by 6-item Montgomery–Åsberg Depression Rating Scale (MADRS-6) scores (p=0.018). ALKS 5461 2mg/2mg also demonstrated statistically significant reductions in 10-item MADRS (MADRS-10) scores compared to placebo (p=0.026). The 1mg/1mg dose of ALKS 5461 showed improvement in depressive symptoms in the study, but did not separate significantly from placebo.

The most commonly reported adverse events for ALKS 5461 in the FORWARD-5 study were nausea, dizziness and fatigue. These findings are consistent with those observed in previously reported studies of ALKS 5461. Alkermes will present comprehensive data from FORWARD-5 at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.

About the FORWARD-5 Study
FORWARD-5 was a phase 3, randomized, double-blind, multicenter, placebo-controlled, sequential parallel comparison design (SPCD) study that evaluated the safety, tolerability and efficacy of two dose levels of ALKS 5461 (2mg/2mg and 1mg/1mg) as adjunctive treatment in patients with MDD who had an inadequate response to a stable dose of either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI). The study randomized 407 subjects.

The study was conducted in two sequential stages: Stage 1 was 5 weeks in duration, Stage 2 was 6 weeks. In Stage 1, the average change from baseline depression scores was calculated for weeks 3 through 5. For Stage 2, the average change was calculated for weeks 3 through 6. The results of Stages 1 and 2 were then averaged. Depression scores were assessed using the 6-item Montgomery–Åsberg Depression Rating Scale (MADRS-6) and MADRS-10. MADRS-6, a subscale of the MADRS-10 assessment tool for depression, focuses on the core symptoms of depression.

About the FORWARD Clinical Program
The FORWARD (Focused On Results With A Rethinking of Depression) pivotal program for ALKS 5461 includes three core phase 3 efficacy studies, as well as additional supportive studies to evaluate the long-term safety, dosing, pharmacokinetic profile and human abuse potential of ALKS 5461. FORWARD-5 is the third phase 3 efficacy study to read out from the FORWARD program. Results from FORWARD-3 and FORWARD-4 were announced in January 2016 and detailed data were presented at the American Society of Clinical Psychopharmacology (ASCP) in June 2016.

Conference Call
Alkermes will host a conference call on Thursday, Oct. 20, 2016 at 5:00 p.m. EDT (10:00 p.m. BST). The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. The conference call will also be webcast on the Investors section of Alkermes’ website at www.alkermes.com. In addition, a replay of the conference call will be available from 8:00 p.m. EDT on Thursday, Oct. 20, 2016 (1:00 a.m. BST, Friday, Oct. 21), through 5:00 p.m. EDT (10:00 p.m. BST) on Thursday, Oct. 27, 2016, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

About ALKS 5461
ALKS 5461 is a proprietary, investigational, once-daily oral medicine that acts as a balanced neuromodulator in the brain and represents a novel mechanism of action for treating MDD. ALKS 5461 consists of samidorphan and buprenorphine, and is designed to rebalance brain function that is dysregulated in the state of depression. In October 2013, the FDA granted Fast Track status for ALKS 5461 for the adjunctive treatment of MDD in patients with an inadequate response to standard antidepressant therapies.

About MDD
According to the DSM-5^® (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), major depressive disorder (MDD) is a condition in which patients exhibit depressive symptoms, such as a depressed mood or a loss of interest or pleasure in daily activities consistently for at least a two-week period, and demonstrate impaired social, occupational, educational or other important functioning. An estimated 17 million people in the U.S. suffer from MDD in a given year,^1,2 the majority of whom may not adequately respond to initial antidepressant therapy.³

About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development and regulatory plans, and commercial potential of ALKS 5461. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether preclinical and clinical results for ALKS 5461 will be predictive of future clinical study results and commercial potential of ALKS 5461; whether future clinical trials for ALKS 5461 will be completed on time or at all; potential changes in cost, scope and duration of the ALKS 5461 clinical development program; whether ALKS 5461 could be shown ineffective or unsafe during clinical studies; whether the preclinical and clinical results of ALKS 5461 will meet the regulatory requirements for approval; whether regulatory submissions may occur or be submitted in a timely manner; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2015, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.

DSM-5^® is a registered trademark of the American Psychiatric Association.

¹ Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun; 62 (6): 617-27.
² U.S. Census.
³ Rush AJ et al (2007) Am J. Psychiatry 163:11, pp. 1905-1917 (STAR*D Study).

$MBRX Announces Reminder for #ConferenceCall on #Annamycin

Call Scheduled for Today to Include General Corporate Update

$MTBC #NetworkNewsWire Releases Exclusive Audio #Interview

NEW YORK, NY / October 20, 2016 / NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of communication solutions for business, today announces the online availability of its interview with Medical Transcription Billing Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, web-based electronic health records, practice management and mHealth solutions. The interview can be heard at http://nnw.fm/mtbc-interview-oct-2016.

Image: https://www.accesswire.com/uploads/mtbc2.jpeg

NNW’s communications solutions include social media outreach, news aggregation and syndication as well as enhanced new release services designed to introduce private and public companies to a wide range of audiences. Leveraging a network of more than 5,000 key distribution outlets, NNW gives its clients a voice – be it through premium articles, audio interviews, video production or other tailored means – to better communicate with the investment community.

MTBC CFO Bill Korn recently joined NNW’s Stuart Smith to discuss MTBC’s operations, recent achievements, and how the company uses its acquisition-based growth strategy to maintain a competitive edge in the healthcare IT market.

Korn, who joined the company in 2013 after 30 years of managing technology companies such as IBM, begins with a brief overview of MTBC’s leadership team before discussing how the company differs from others in the market.

“MTBC has two cores strengths that distinguish us from most of the 1,500 other healthcare IT companies. We have an integrated cloud-based technology platform, which we developed in-house, and we have wholly owned offshore subsidiaries with 1,600 employees in four countries, with labor costs that average about 10% of the labor costs in the U.S. This allows us to provide services which are labor intensive even though we use our technology, and we can deliver these services much less expensively than our customers or competitors can provide them,” explains Korn.

With these foundations in place, MTBC achieved three main accomplishments in 2016. The company recorded three quarters of positive EBITDA since its IPO in 2014; raised $7.5 million of non-convertible preferred stock on the NASDAQ; and closed its acquisition of MediGain, marking its tenth acquisition since the IPO and largest acquisition to-date.

In early October, MTBC acquired substantially all of the assets of MediGain, LLC and its Millennium Practice Management, LLC affiliate for a total purchase price of $7 million, representing a “significant discount as compared to the industry norm of at least one times annualized revenues for a company of MediGain’s size,” says Korn.

Wrapping up the interview, Korn explains several benefits of the MediGain acquisition, including the expansion of the company’s global team of professionals and expectations for increased revenues.

“We believe that our newly acquired business will contribute to our positive adjusted EBITDA by the first quarter of 2017. By growing our overall revenue greatly through this acquisition, MTBC expects to generate significant operating leverage … the incremental profits for this acquisition are expected to greatly exceed the company’s cost of capital,” he says. “This acquisition should be accretive to our shareholders in 2017.”

About Medical Transcription Billing, Corp. (NASDAQ: MTBC)

Medical Transcription Billing, Corp. is a healthcare information technology company that provides a fully integrated suite of proprietary web-based and mobile health solutions, together with related business services, to healthcare providers throughout the United States. Our integrated Software-as-a-Service (or SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

For more information on MTBC, please visit www.mtbc.com

Follow MTBC on TWITTER, LINKEDIN and FACEBOOK.

About NetworkNewsWire

NetworkNewsWire (NNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, NNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, NNW’s innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit www.NetworkNewsWire.com.

Please view full disclaimers at the following link: www.NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.net

$ADTN Primes a Countrywide #Gfast Deployment in #Israel with #Bezeq

ADTRAN®, Inc., (NASDAQ: ADTN), a leading provider of next-generation open networking solutions, today announced it is the prime project vendor in a countrywide G.fast deployment for Israeli incumbent operator Bezeq. The initial phase, involving a suite of G.fast distribution point unit (DPU) and CPE solutions from ADTRAN’s Mosaic© SD-Access portfolio, will represent one of the largest ongoing G.fast deployments in the world. The mass G.fast rollout will quickly establish Israel at the forefront of digital nations, bringing ultrafast broadband capabilities to citizens at a record pace. ADTRAN’s IP68 sealed G.fast solutions, serving as the foundational element for Bezeq’s G.fast plans, allow deployment with confidence due to ADTRAN’s global leadership in the growing sealed micro DSLAM segment.

“ADTRAN’s advanced G.fast innovation makes it the clear choice for our G.fast rollout, helping us rapidly serve customers across Israel with new, transformative broadband services,” said Bezeq CTIO, Yaki Zano. “ADTRAN’s collaborative involvement in our strategic development has given us a robust and flexible technology roadmap for the future of our broadband access network, ready to confront new opportunities.”

The announcement is validation of ADTRAN’s global G.fast technology leadership and follows a series of intensive lab and field trials with the operator during 2016. Allied to the success of these trials was ADTRAN’s partnership approach to addressing Bezeq’s unique Gigabit broadband goals within a short timeframe.

“Bezeq is assuring a bright, sustainable future for ultrafast and Gigabit broadband services in Israel, applying G.fast in a wide range of varied applications so that the maximum number of subscribers across the country are able to benefit without waiting for FTTP to arrive,” said Ronan Kelly, CTO for EMEA and APAC at ADTRAN. “ADTRAN G.fast solutions are built for superior versatility, robustness and performance, with software-defined networking (SDN) principles that make Bezeq’s network more flexible, open and ready to exploit dynamically.”

Bezeq is leveraging ADTRAN’s G.fast solutions in a variety of locations and deployment scenarios including FTTB, FTTCab and both aerial and subterranean FTTdp. Each of the DPUs involved in Bezeq’s deployment utilizes ADTRAN’s renowned sealed micro DSLAM enclosures and is physical layer agnostic to ensure rapid service provisioning and activation, even within multi-vendor FTTx infrastructures. In addition, ADTRAN DPUs are chipset agnostic, allowing them to remain at the forefront of G.fast innovation, independent of the pace of development of specific chipset vendors.

As Bezeq develops its network infrastructure for more programmable, flexible Gigabit service delivery, another key consideration is enabling increased automation utilizing ADTRAN’s unique software-defined network virtualisation capabilities.

About ADTRAN

ADTRAN, Inc. is a leading global provider of networking and communications equipment. ADTRAN’s products enable voice, data, video and Internet communications across a variety of network infrastructures. ADTRAN solutions are currently in use by service providers, private enterprises, government organizations, and millions of individual users worldwide. For more information, please visit www.adtran.com.

About Bezeq

Bezeq is Israel’s leading telecommunications service provider. Established in 1984, the Company has led Israel into the new era of communications, based on the most advanced technologies and services. Bezeq and its subsidiaries offer the full range of communications services including domestic, international and cellular phone services; broadband Internet and other data communications; satellite-based multi-channel TV; and corporate networks. For more information, please visit http://www.bezeq.co.il/.

$NVIV #FoothillsMedicalCentre in #Calgary, #Alberta Newest Site for #INSPIRE Study

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Foothills Medical Centre in Calgary, Alberta has been added as a Canadian clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Foothills Medical Centre is the largest hospital in Alberta and is one of the most recognized medical facilities in Canada, providing advanced healthcare services to over two million people from Calgary and southern Alberta, the northwestern United States, southeastern British Columbia, and southern Saskatchewan.

“InVivo’s Neuro-Spinal Scaffold is one of the more innovative approaches to treating acute spinal cord injury in recent history and we look forward to being a part of the INSPIRE study,” said Steven Casha, M.D., Ph.D., Assistant Professor of Neurosurgery in the Department of Clinical Neurosciences and Principal Investigator at the study site.

Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to welcome Dr. Casha and his team at the Foothills Medical Centre to the INSPIRE study. We will continue to expand our footprint in both the US and Canada.”

A new CEO’s Perspective discussing the current status of the INSPIRE study can be found on the InVivo Therapeutics website: http://www.invivotherapeutics.com/about-invivo/ceo-perspective/

There are now 24 clinical sites participating in the clinical study:

• Banner University Medical Center, Tucson, AZ
• Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, MO
• Ben Taub Hospital/Baylor College of Medicine, Houston, TX
• Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix, AZ
• Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte, NC
• Cooper Neurological Institute, Camden, NJ
• Foothills Medical Centre, Calgary, Alberta, Canada
• Goodman Campbell Brain and Spine/Indiana University Health Neuroscience Center, Indianapolis, IN
• Hospital of the University of Pennsylvania, Philadelphia, PA
• Keck Hospital of University of Southern California, Los Angeles, CA
• Medical College of Wisconsin/Froedtert Hospital, Milwaukee, WI
• Mount Sinai Hospital, New York, NY
• Northwestern Medicine, Chicago, IL
• Oregon Health & Science University, Portland, OR
• Rutgers New Jersey Medical School, Newark, NJ
• Thomas Jefferson University Hospital, Philadelphia, PA
• Toronto Western Hospital, Toronto, ON, Canada
• University of California, Davis Medical Center, Sacramento, CA
• University of California, San Diego Medical Center, San Diego, CA
• University of Kansas Medical Center, Kansas City, KS
• University of Louisville Hospital, Louisville, KY
• University of Pittsburgh Medical Center Presbyterian, Pittsburgh, PA
• University of Virginia Health System, Charlottesville, VA
• Vidant Medical Center, Greenville, NC

For more information, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release or the CEO Perspective referred to herein that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, the expected timing of full enrollment in the INSPIRE study, the timing of the submission of the Humanitarian Device Exemption (HDE), the timing for opening of the pilot cervical SCI study, and the company’s anticipated cash balance. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the ability to complete the INSPIRE study and submit an HDE; the company’s ability to receive regulatory approval for the Neuro-Spinal Scaffold; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

InVivo Therapeutics
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

$AVGR Announces Expanded #FDA Indications for #Pantheris

First-Ever Image-Guided Atherectomy Device Receives Dual Clearance for Diagnostic Imaging and Treatment for Peripheral Artery Disease

REDWOOD CITY, Calif., Oct. 19, 2016 — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the company has received expanded indications from the U.S. Food and Drug Administration (FDA) recognizing the Pantheris™ Lumivascular atherectomy system as a technology that can be used for both therapeutic and diagnostic purposes.

Pantheris is the first and only image-guided atherectomy device to receive clearance for diagnostic imaging as well as for the simultaneous treatment of PAD. This expanded indication clarifies that, in addition to treatment of PAD, Pantheris may be used by physicians to identify the vessel lumen and wall structures such as intima, internal elastic lamina (IEL), media, external elastic lamina (EEL) and stent struts, as well as vessel morphologies such as calcium, thrombus, fibroatheromas, and necrotic cores.

“I am thrilled that Pantheris is now recognized as providing important diagnostic imaging information that enhances physicians’ ability to deliver the most advanced treatments for vascular disease,” said John B. Simpson, Ph.D., M.D., the company’s founder and executive chairman. “This is one more step toward establishing Lumivascular technology as a premier interventional platform for physicians.”

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology in the Pantheris catheter allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT. In the past, physicians have had to rely solely on X-ray as well as touch and feel to guide their tools while they try to treat complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices to treat PAD lesions using the guidance of OCT images generated from inside the artery. By relying upon OCT images as an adjunct to fluoroscopy, exposure to ionizing radiation may be reduced for healthcare workers and patients.

“The FDA clearance of Pantheris as a diagnostic tool reflects what we as clinicians have already seen first-hand in our practices: that Pantheris OCT images provide important clinical information during our procedures, allowing us to see complicated plaque characteristics in real time as we treat the vessel,” said Suhail Dohad, M.D., interventional cardiologist with Cedars Sinai Hospital, Los Angeles, Calif. “With Pantheris, we can now reliably assess disease extent while simultaneously treating disease, allowing a greater level of accuracy and confidence.”

About Avinger, Inc.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.

Investor Contact:
Matt Ferguson
Avinger, Inc.
(650) 241-7917
ir@avinger.com

$HH Expands #WellnessSupportNow

Solution Increases Enrollment of Health Coaching, Cuts Costs of Wellness Programs, and Improves Member Experience

OLATHE, Kan., Oct. 19, 2016  — Hooper Holmes, Inc. (NYSE MKT:HH), a national leader in corporate wellness and health screenings, is pleased to announce that following the success of earlier pilots, Wellness Support Now for Channel Partners will formally become part of Hooper’s suite of products and services.  Leveraging Hooper’s network of more than 10,000 Health Professionals nationwide, Hooper’s wellness vendor partners can now choose to offer a health consultation upgrade, immediately following an onsite screening, whereby the Professional Health Educators are able to inform participants of other health improvement programs available as they continue their journey to better health.

“The program is a win-win for all,” said Henry Dubois, President and CEO of Hooper Holmes, Inc.  “Our Professional Health Educators leverage a face-to-face teachable moment to instruct participants and help them find the right wellness programs, at the right time.  Our wellness vendor partners benefit from increased enrollment and engagement into their respective health improvement programs while reducing administrative expenses and improving the member experience.  Indications from clients already on Hooper’s Wellness Support Now platform are promising as participant enrollment into Health Coaching programs has increased 40%-50%+.”

As part of Wellness Support Now, Professional Health Educators will capitalize on access to real-time health information via Hooper’s proprietary ScreeningPro tablet technology and kick-start a member’s journey to better health.  The Health Educators guide participants into the right action plans and health improvement programs based on the participant’s health risk profile.  Hooper’s wellness vendor partners are able to deliver a more cohesive, positive member experience while generating savings from improved efficiency and more effective participant engagement outreach.

For additional information or to submit a request for a proposal, please contact us.

About Hooper Holmes
Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs.

For further information:

Hooper Holmes, Inc.
Henry E. Dubois
President and CEO
(913) 764-1045

Investors: Andrew Berger
S.M. Berger & Company
(216) 464-6400

$DRWI Equipment Selected for #Sprint Network

Sprint expands its toolkit to provide customers with more capacity and faster data speeds in high-traffic locations

Media Contact:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
+1-613-599-9991 ext 2262

Media Contact:
Becky Obbema
Interprose
(for DragonWave)
Becky.Obbema@interprosepr.com
+1-408- 778-2024

Investor Contact:
Patrick Houston
CFO
DragonWave Inc.
phouston@dragonwaveinc.com
+1-613-599-9991 ext. 2278

$BSPM Completes Previously Announced Registered Direct Financing

XIANYANG, China, Oct. 18, 2016  — Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) (“Biostar”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that it completed the sale of 425,000 shares of common stock at the price of $4.50 per share, and warrants to purchase 212,500 shares of common stock to institutional investors for gross proceeds of approximately $1.91 million. The warrants will be exercisable six months and one day from the date of the closing of the offering at an exercise price of $5.55 per share and expire 3 1/2 years from the date of issuance.

FT Global Capital, Inc. acted as the exclusive placement agent for the offering. Biostar plans to use the net proceeds of this offering for working capital and general corporate purposes.

A shelf registration statement (File No. 333-192963) relating to the offering has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A prospectus supplement relating to the offering has been filed by Biostar with the SEC. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at http://www.sec.gov, or from request at Biostar from No. 588 Shiji Avenue Xianyang City, Shaanxi Province, People’s Republic of China 712046.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Biostar in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. For more information contact: Biostar Pharmaceuticals, Inc.; Tel: +86-29-3368-6638; Email: office@aoxing-group.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ materially from the Company’s expectations. Factors that could cause actual results to differ materially from those stated or implied by the Company’s forward-looking statements are disclosed in its filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s judgment as of the time of this release. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

$ABEO Gets #OrphanDrug Designation in #EU for #ABO102 in #Sanfilippo

$MMYT & #Naspers #ibiboGroup to Consolidate their #Indian #Travel Businesses

Two leading travel groups in India, MakeMyTrip Limited (NASDAQ:MMYT) and ibibo Group (owned by global technology group Naspers Limited (JSE: NPN.SJ and LSE: NPSN)), have agreed to pursue a transaction that will combine the two businesses under MMYT, creating one of the leading travel groups in India that provides a one-stop shop for all Indian travellers and serves as a critical partner for travel industry suppliers.

The combination will bring together a bouquet of leading consumer travel brands, including MakeMyTrip, goibibo, redBus, Ryde and Rightstay, which together processed 34.1 mm transactions during FY2016.

The transaction is expected to unlock value for customers, supply partners and shareholders, by combining the complementary strengths of each business. MakeMyTrip brings its strong brand, robust mix of domestic and outbound hotels and packages business and strong position in the air ticketing business. ibibo Group, via its brand goibibo and redBus, comes with a strong presence in various fast growing travel segments including hotels, bus bookings and air ticketing.

Following the closing of the proposed transaction, Founder Deep Kalra will remain Group CEO and Executive Chairman of MakeMyTrip and Co-founder Rajesh Magow will continue to remain CEO India of MakeMyTrip. Founder and CEO of ibibo Group, Ashish Kashyap, will join MakeMyTrip’s executive team as a Co-founder and President of the organization.

Deep Kalra, Chairman and Group CEO of MakeMyTrip, said: “Today’s announcement is a significant step forward for the rapidly growing travel industry in India. We expect this deal to create an even more scalable business with the expertise to transform the booking experience for Indian travellers. I am delighted to be leading such a strong team in our next chapter of high-growth in this dynamic industry.”

Rajesh Magow, co-founder and CEO India of MakeMyTrip added: “We welcome the ibibo team to the newly expanded MakeMyTrip family. The combination of these two enterprises, with their deep understanding of customer preferences, will help us provide an even stronger value proposition to our users and offer further career growth opportunities for all employees”

Ashish Kashyap, CEO ibibo Group, said: “Since I founded ibibo in 2007, we have innovated and grown to become one of the leading travel companies in India, providing solutions not just for travellers, but for suppliers too. Deep, Rajesh and I saw a great opportunity to join forces, and I am excited that this merger enables all of us to continue a great journey together as the leading travel group in India.”

According to Bob van Dijk, CEO Naspers: “India is a key market for Naspers, and this deal reinforces our commitment to the country. ibibo and MakeMyTrip have built leading companies through their innovative use of technology to create exceptional experiences for people traveling throughout India and, increasingly, beyond. Today’s announcement underlines the continued ambition of Deep, Rajesh and Ashish and their teams, and I look forward to seeing the future success of this new and even stronger business.”

Naspers and Tencent, through their jointly owned holding company (91% owned by Naspers and 9% owned by Tencent), are selling ibibo Group to MakeMyTrip in exchange for an issuance of new shares by MakeMyTrip. Upon closing of the transaction, MakeMyTrip will own 100% of ibibo Group. Naspers and Tencent will become the single largest shareholder in MakeMyTrip, owning a 40% stake, and will contribute proportionate working capital upon closing.

Additionally, prior to closing , the US$180 million, 5-year convertible notes issued by MakeMyTrip Limited to Ctrip.com International, Ltd. (“Ctrip”) (NASDAQ: CTRP) in January 2016 will also be converted into common equity, resulting in Ctrip having an approximately 10% stake in the combined entity.

The transaction is expected to close by the end of December 2016 and is subject to approval by MakeMyTrip shareholders and regulatory approvals.

Morgan Stanley is acting as exclusive financial advisor to MakeMyTrip and has also provided a fairness opinion to the Board of MakeMyTrip. Latham and Watkins, S&R Associates and Appleby are acting as legal advisors to MakeMyTrip. Goldman Sachs is acting as exclusive financial advisor to ibibo and Naspers, while Cravath, Swaine & Moore, Trilegal and BLC Roberts are acting as legal advisors.

We shall be hosting a conference call today at 20:00 IST / 16:30 CET / 10:30 EST. Conference call details below.

About MakeMyTrip

MakeMyTrip Limited is the parent company of MakeMyTrip (India) Private Limited, MakeMyTrip Inc. (USA), MakeMyTrip FZ LLC (UAE), Luxury Tours & Travel Pte Ltd (Singapore), Luxury Tours (Malaysia) Sdn Bhd, the Hotel Travel Group (Thailand) and the ITC Group (Thailand). The Company’s services and products include air tickets, customized holiday packages, hotel bookings, railway tickets, bus tickets, car hire and facilitating access to travel insurance. Through its primary websites, www.makemytrip.com, www.hoteltravel.com and www.easytobook.com and other technology-enhanced platforms, the Company provides access to all major domestic full-service and low-cost airlines operating to and from India, all major airlines operating to and from India, over 33,000 hotels and guesthouses in India, more than 310,000 hotels outside India, Indian Railways and several major Indian bus operators.

About ibibo:

The ibibo Group operates integrated travel properties such as Goibibo.com (leading hotels and air aggregator), redBus.in (leading online bus ticketing platform), YourBus (Vehicle tracking application), and recently launched car sharing app, ibibo Ryde. The company’s mission is to organize the transportation and accommodation industry and connect it with travellers. At 7.65mn unique transactions a quarter, ibibo is one of the leading travel companies in India.

For more information, please visit www.ibibo.com.

About Naspers:

Founded in 1915, Naspers is a global internet and entertainment group and one of the largest technology investors in the world. Operating in more than 130 countries and markets with long-term growth potential, Naspers builds leading companies that empower people and enrich communities. It runs some of the world’s leading platforms in internet, video entertainment, and media.

Naspers companies connect people to each other and the wider world, help people improve their daily lives, and entertain audiences with the best of local and global content. Every day, millions of people use the products and services of companies that Naspers has invested in, acquired or built, including Allegro, Avito, Brainly, Codecademy, eMAG, Flipkart, letgo, Media24, Movile, MultiChoice, OLX, PayU, ShowMax, SimilarWeb, Twiggle, and Udemy. Similarly, hundreds of millions of people have made the platforms of its associates Tencent (www.tencent.com; SEHK 00700) and Mail.ru (www.corp.mail.ru; LSE: MAIL) a part of their daily lives.

Naspers is listed on the Johannesburg Stock Exchange (NPN.SJ) and has an ADR listing on the London Stock Exchange (LSE: NPSN).

For more information, please visit www.naspers.com.

Important Information for Investors and Shareholders

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed transaction will be submitted to the shareholders of MakeMyTrip for their consideration. MakeMyTrip will provide a proxy statement to its respective shareholders for consideration of the proposed transaction. Investors and security holders are urged to read the proxy statement and any other relevant documents filed with the SEC when they become available, as well as any amendments or supplements to those documents, because they will contain important information about MakeMyTrip, ibibo Group and the proposed transaction. Investors and security holders will be able to obtain a free copy of the proxy statement, as well as other filings containing information about MakeMyTrip and the transaction free of charge at the website of Securities and Exchange Commission (SEC) at http://www.sec.gov. In addition, the proxy statement, the SEC filings that may be incorporated by reference in the proxy statement and the other documents filed with the SEC by MakeMyTrip may be obtained free of charge by directing such request to request to Jonathan Huang, Vice President – Investor Relations at Jonathan.Huang@makemytrip.com or +1 (917) 769-2027.

MakeMyTrip and its directors, executive officers, and certain other members of management and employees may be deemed to be participants in the solicitation of proxies in favor of the proposed transaction from the shareholders of MakeMyTrip. Information about the directors and executive officers of MakeMyTrip is set forth in MakeMyTrip’s annual report on Form 20-F, which was filed with the SEC on June 14, 2016. Additional information regarding participants in the proxy solicitation may be obtained by reading the proxy statement regarding the proposed transaction when it becomes available.

Special Note Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, but are not limited to, (i) statements about the benefits of the acquisition of ibibo Group by MakeMyTrip, including financial and operating results and synergy benefits that may be realized from the acquisition and the timeframe for realizing those benefits; (ii) MakeMyTrip and ibibo Group’s plans, objectives, expectations and intentions; (iii) other statements contained in this communication that are not historical facts; and (iv) other statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “goal,” “strategy,” “future,” “likely,” “may,” “should,” “could,” “will,” and words of similar meaning or similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, forward-looking statements are based only on current beliefs, assumptions, and expectations regarding the future of MakeMyTrip’s business, including the effects of the proposed acquisition of ibibo Group by MakeMyTrip, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are inherently subject to significant business, economic and competitive uncertainties, risks, and contingencies, which may include third-party approvals, many of which are beyond our control and are difficult to predict. Therefore, readers of this communication are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

The following factors, among others, could cause actual results to differ materially from those expressed or implied in the forward-looking statements: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; (ii) the inability to complete the transaction due to the failure to obtain the required shareholder approval; (iii) the inability to satisfy the other conditions specified in the transaction agreement, including without limitation, the receipt of necessary governmental or regulatory approvals required to complete the transaction; (iv) the inability to successfully integrate the businesses of MakeMyTrip and ibibo Group or to integrate the businesses within the anticipated timeframe; (v) the risk that the proposed transactions disrupt current plans and operations, increase operating costs and the potential difficulties in customer or supplier loss and employee retention as a result of the announcement and consummation of such transactions; (vi) the inability to recognize the anticipated benefits of the combination of MakeMyTrip and ibibo Group, including the realization of revenue and cost synergy benefits and to recognize such benefits within the anticipated timeframe; (vii) the outcome of any legal proceedings that may be instituted against MakeMyTrip, ibibo Group or others following announcement of the transaction; and (viii) the possibility that MakeMyTrip or ibibo Group may be adversely affected by other economic, business, and/or competitive factors.

Additional information concerning these and other important factors can be found within MakeMyTrip’s filings with the SEC, which discuss the foregoing risks as well as other important risk factors that could contribute to such differences or otherwise affect our business, results of operations and financial condition. Statements in this communication should be evaluated in light of these important factors. The forward-looking statements in this communication speak only as of the date they are made. Except for the ongoing obligations of MakeMyTrip to disclose material information in accordance with law, MakeMyTrip does not undertake any obligation to, and expressly disclaims any such obligation to, update or alter any forward-looking statement to reflect new information, circumstances or events that occur after the date such forward-looking statement is made unless required by law.

$OPCO CFO to Present at the #MicroCapConference in #Philadelphia

ARLINGTON, VA / October 18, 2016 / OurPet’s Company (OTC: OPCO) Chief Financial Officer Scott Mendes will be presenting at this year’s MicroCap Conference taking place October 24-25 in Philadelphia at the Hotel Monaco, joining 60 other presenting companies in the microcap universe.

Mendes make his presentation on October 25 from 5-5:30 p.m. to demonstrate the company’s innovative, trend-setting pet products and accessories sold through leading pet specialty and Internet retailers, direct-mail catalog, and food, drug and mass merchandisers.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

If you are a private investor or institutional investor interested in learning more about the conference, please click here.

About the OurPet’s Company

The OurPet’s Company (OTCQX: OPCO) designs, produces and markets a broad line of innovative, trend-setting pet products and accessories sold under the OurPets® and Pet Zone® brands domestically and internationally. OurPets® and Pet Zone® products are sold through leading pet specialty retailers, food, drug and mass merchandisers, direct-mail catalog and internet retailers. Since its founding in 1995, the OurPet’s Company has been building an extensive intellectual property portfolio with more than 170 patents in either issued or pending status all devoted to solving problems related to the human/pet bond. OurPet’s was named a Weatherhead Top 100 Fastest Growing Company in Northeast Ohio in 2013 and has been a Lake-Geauga County Fast Track 50 Hall of Fame local business success winner for the last eight consecutive years. In addition, the OurPet’s Company was named 2015 Business of the Year by the Painesville Area Chamber of Commerce. Investors and customers may visit www.ourpets.com and www.petzonebrand.com for more information about the Company, its products and brands.

Media Contact:

Peter Ostapowicz
Marketing Communications Specialist

Investor Relations:

DreamTeamNetwork (DTN)
Austin, TX
www.DreamTeamNetwork.com
512.758.8877 Office

$GMLP Exchange of Incentive Distribution Rights

HAMILTON, Bermuda, Oct. 14, 2016  — Golar LNG Partners LP (NASDAQ: GMLP) (the “Partnership”) announced today that it has entered into an agreement with Golar LNG Limited (“Golar”) and Golar GP LLC (the “GP”) to exchange all of the existing incentive distribution rights (“Old IDRs”) for (i) the issuance of a new class of incentive distribution rights (“New IDRs”) and an aggregate of 2,994,364 common units and an aggregate of 61,109 general partner units on the closing date of the exchange (the “Closing”) and (ii) an aggregate of up to 748,592 additional common units and up to 15,278 additional general partner units (collectively, the “Earn-Out Units”) that may be issued subject to certain conditions described below  (collectively, the “Transaction”).  The Earn-Out Units represent an aggregate of 20% of the total units to be issued in connection with the Transaction.  If the Partnership issues the Earn-Out Units, the Partnership will have issued an aggregate of 3,742,956 common units and 76,387 general partner units in connection with the Transaction.

The Partnership will issue 50% of the Earn-Out Units if the Partnership pays a distribution of available cash from operating surplus pursuant to the terms of the Partnership’s agreement of limited partnership, as amended and restated in connection with the Transaction (the “Partnership Agreement”), on each of the outstanding common units of the Partnership (the “Common Units”) equal to or greater than $0.5775 per Common Unit in respect of each of the quarterly periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017.  The Partnership will issue the remaining 50% of the Earn-Out Units if the Partnership has issued the first 50% of the Earn-Out Units and the Partnership pays a distribution of available cash from operating surplus pursuant to the terms of the Partnership Agreement on each of the outstanding Common Units equal to or greater than $0.5775 per Common Unit in respect of each of the quarterly periods ended December 31, 2017, March 31, 2018, June 30, 2018 and September 30, 2018.

The terms of the New IDRs are effective with respect to the distribution for the quarter ended December 31, 2016, payable in February 2017.  The New IDRs provide for distribution “splits” between the IDR holders and the holders of Common Units equal to those applicable to the Old IDRs, which have been cancelled. However, the New IDRs provide for higher target distribution levels, as set forth in the table below. In addition, in connection with the Transaction, the minimum quarterly distribution will be $0.5775 per common unit (or $2.31 per unit on an annualized basis).

The Transaction was approved by the Board of Directors of the Partnership (the “Board”) upon the recommendation of the Conflicts Committee of the Board comprised of the independent directors, who retained an independent financial advisor.

The following table compares the target distribution levels and distribution splits between the general partner and the holders of Common Units under the Old IDRs and under the New IDRs:

The Partnership believes that the Transaction will reduce the Partnership’s cost of equity and better positions it to pursue strategic acquisitions and grow distribution capacity. The Partnership expects to enter into preliminary discussions with Golar regarding the potential acquisition of an interest in the FLNG unit, the Golar Hilli, which is on schedule to commence its 8 year contract with Perenco Cameroon by September 30, 2017. In the event the Partnership acquires an interest in the Golar Hilli, it is expected to add significantly to the Partnership’s revenue backlog and reduce the exposure to the existing time charters that run off at the end of 2017.

There can be no assurance that the Partnership will acquire an interest in the Golar Hilli. Any such acquisition would be dependent on the attractiveness of the overall financing package, including the pricing of any equity financing, and the approval of the boards of directors of the Partnership and Golar.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning future events and the Partnership’s operations, performance and financial condition.  Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “believe”, “anticipate”, “expect”, “estimate”, “project”, “will be”, “will continue”, “will likely result”, “plan”, “intend” or words or phrases of similar meanings. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the Partnership’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to:

• whether or not the Transaction described in this press release will have the anticipated benefits on the Partnership;
• the Partnership’s ability to acquire an interest in the Golar Hilli from Golar and to realize the anticipated benefits of any such acquisition;
• changes in the Partnership’s distributions to unitholders;
• the Partnership’s ability to implement its growth strategies and other plans and objectives for future operations;
• the Partnership’s future revenues, expenses, financial condition and results of operations;
• the ability of the Partnership to refinance debt and the Partnership’s ability to incur additional debt and the terms thereof;
• the Partnership’s ability to make additional borrowings and to access debt and equity markets;
• charter commencement and termination dates and extensions of charters; and
• other factors listed from time to time in the reports and other documents the Partnership files with the United States Securities and Exchange Commission.

New factors emerge from time to time, and it is not possible for the Partnership to predict all of these factors. Further, the Partnership cannot assess the impact of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. The Partnership does not intend to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Partnership’s expectations with respect thereto or any change in events, conditions or circumstances on which any such statement is based.

Hamilton, Bermuda
October 14, 2016

Investor relations enquiries:
Golar Management Limited
Graham Robjohns – + 44 207 063 7900

Stuart Buchanan – + 44 207 063 7900
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

$QTNT Announces $120 Million Secured #DebtFinancing

JERSEY, Channel Islands, Oct. 14, 2016  — Quotient Limited (“Quotient”) (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the completion of a private placement of up to $120 million of 12% Senior Secured Notes due 2023. At the initial closing of the transaction, Quotient issued $84 million of notes and received net proceeds of approximately $79 million after expenses. Quotient will issue an additional $36 million of notes to note purchasers upon public announcement of field trial results for the MosaiQ™ IH Microarray that demonstrates greater than 99% concordance for the detection of blood group antigens and greater than 95% concordance for the detection of blood group antibodies when compared to predicate technologies for a pre-defined set of blood group antigens and antibodies. Quotient intends to use the net proceeds from this transaction, among other things, to repay all outstanding obligations to MidCap Financial Trust under its existing loan agreement and for general corporate purposes. Morgan Stanley & Co. LLC acted as sole placement agent for the transaction.

The notes bear interest at a rate of 12% per annum, payable semi-annually on April 15 and October 15 of each year, commencing on April 15, 2017. On each payment date, commencing on April 15, 2019, Quotient will pay an installment of principal of the notes pursuant to a fixed amortization schedule. The stated maturity date of the notes is October 15, 2023. The notes are redeemable at the option of Quotient at a redemption price that includes a make-whole premium until October 14, 2018 and, thereafter, at a redemption price that includes a declining premium to par over four years. The notes are guaranteed by Quotient’s subsidiaries and secured by substantially all of the property and assets (subject to certain exclusions) of Quotient and its subsidiaries.

Additionally, Quotient has sold a royalty right to the note purchasers, representing a right to receive an aggregate 2.0% royalty payment on net sales of MosaiQ™ instruments and consumables in the donor testing market in the European Union and the United States. The royalty will be payable beginning on the date that Quotient or its affiliates enters into a contract for the sale of MosaiQ™ instruments or consumables in the donor testing market in the European Union or the United States and ending on the last day of the calendar quarter in which the eighth annual anniversary of the first contract date occurs.

For more information regarding the terms and conditions of the notes, please refer to the Current Report on Form 8-K filed today by Quotient with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities have not been and will not be registered under the Securities Act of 1933 or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933 and applicable state securities laws.

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the intended use of proceeds from the secured debt offering and the issuance of the additional notes. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the risks and uncertainties associated with the application of the net proceeds from the secured debt offering as well as the other risks set forth in the company’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: 
Stephen Unger, 
Chief Financial Officer 
stephen.unger@quotientbd.com; 
(212) 228-7572

$AKTX Appoints New Members to its Board of Directors

NEW YORK and LONDON, Oct. 14, 2016 — Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment of Robert Ward to its Board of Directors. Mr. Ward brings over twenty-five years of pharmaceutical experience to the Board and follows recent Board appointee Donald Williams who was elected to the Board in June 2016.  Akari also announced that Mark Cohen has stepped down from the Board in order to serve as outside counsel to Akari on US intellectual property matters. David Byrne, who was appointed to the Board of Directors in April 2016, has been appointed to the compensation committee.

Robert Ward, who has been appointed chair of the nominating and governance committee, has a diverse and extensive pharmaceutical industry background spanning over 25 years.  Mr. Ward serves as President and Chief Executive Officer and a member of the Board of Radius Health, Inc., a NASDAQ listed biopharmaceutical company, since December 2013. During his tenure, Radius Health has completed late stage development of its lead compound and filed the first global regulatory new drug applications, successfully raised over $750 million in private and public financings – including an initial public offering in 2014, and advanced other novel compounds/drug delivery technologies in clinical development.  Prior to leading Radius, Mr. Ward was Vice President for Strategy and External Alliances for AstraZeneca (AZ).

At the annual general meeting of shareholders in June 2016, Donald Williams was elected to Akari’s Board of Directors.  Following his election, he was appointed chair of the audit committee.  Mr. Williams is a 35-year veteran of the public accounting industry.  Mr. Williams spent 18 years as a partner at Ernst & Young and the last seven years as a partner at Grant Thornton.  Mr. Williams’ career focused on private and public companies in the technology and life sciences sectors.  During the last seven years at Grant Thornton, he served as the National Leader of Grant Thornton’s Life Sciences Practice and the Managing Partner of the San Diego Office.

Dr. Ray Prudo, Executive Chairman of Akari, stated, “We are delighted to welcome Bob Ward and Don Williams to the Akari Board and we look forward to the benefits their experienced counsel will provide as we advance our portfolio.”

Mr. Cohen, who was Chairman of Celsus Therapeutics, Plc which merged in September 2015 with Volution Immuno Therapeutics, SA and then changed its name to Akari Therapeutics, Plc, served as Vice Chairman of the Board, chair of the nominating and governance committee and as a member of the compensation committee.  Mr. Cohen played a significant role in the merger of Celsus and Volution, and was instrumental in the successful integration of the two companies.  Mr. Cohen, who is a Senior Partner and Chair of the Life Science Practice Group at the firm of Pearl Cohen Zedek Latzer Baratz, will, through his firm, be outside counsel to the company on US intellectual property matters.

Dr. Gur Roshwalb, CEO of Akari, stated, “We wish to thank Mark for his tremendous contributions to Akari as a director and trusted advisor and we look forward to his assistance and counsel in further developing Akari’s intellectual property position.”

About Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. Akari’s lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: an inability or delay in obtaining required regulatory approvals for Coversin and any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K filed on March 23, 2016. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Contact: 

Investor & Media Contact:
The Trout Group
Tricia Truehart		
ttruehart@troutgroup.com	
646–378–2953 

Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210